Archives

Patient Safety: Your Personal Medication Error Rate: Checkpoints and Reality Checks

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

  • Differentiate systemic approaches to medication errors and individual (personal) responsibilities for medication errors
  • Outline various causes for medications errors that can be traced back to individuals
  • Discuss how unique work habits influence the propensity to make errors
  • Apply methods to reduce an individual’s medication error rate

Cartoon character holding up traffic sign that says 'oops!'

Release Date:

Release Date:  May 1, 2023

Expiration Date: May 1, 2026

Course Fee

Pharmacists: $7

Pharmacy Technicians: $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-0000-23-016-H05-P

Pharmacy Technician: 0009-0000-23-016-H05-T

Session Codes

Pharmacist:  23YC16-XVK33

Pharmacy Technician:  23YC16-TXP82

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-016-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Amanda Choi, PharmD
Pharmacist
Backus Hospital
Norwich, CT

Carren Jepchumba, PharmD
Pharmacy Manager
Kroger Health
Indianapolis, IN

Jeannette Wick, RPh, MBA, FASCP
Dir. Office of Pharmacy Professional Development
UConn School of Pharmacy
Storrs, CT


 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Drs. Choi and Jepchumba and Ms. Wick have no relationships with ineligible companies and therefore have nothing to disclose.

 

ABSTRACT

Pharmacists and pharmacy technicians must be careful not to make
errors, but errors slip through from time to time. Organizations (healthcare systems,
hospitals, and pharmacies) often use systems-based approaches to error
prevention. Pharmacy employees need to know about systems-based approaches,
but they also need to know about approaches they can use themselves to reduce
their own chances of error. This activity describes factors that increase the
likelihood of error and methods that are proven to help individuals focus. We
discuss–and strongly recommend–knowing your limit, tracking and recording errors,
collaborating with coworkers, employing tools that increase accuracy, and
stopping the workflow when things “feel” wrong.

CONTENT

Content

INTRODUCTION

Pharmacists and pharmacy technicians strive to provide safe, high-quality care to people when they are unwell, but sometimes we make errors. No one likes to make an error, and in our field, errors can have devastating consequences: preventable illness and injury, unnecessary hospitalizations, disability, and sometimes even death. Experts who have extrapolated data indicate that medical errors now account for 9.5% of all deaths in the United States, which if true, would make medical mistakes the third leading cause of death after heart disease and cancer.1

Addressing issues systemically has become commonplace in healthcare systems. Most of us know that the first step in resolving medication errors is being able to identify where errors occur and factors that contribute to their occurrence. Tracking in this way allows us to integrate preventive measures into our systems and habits to reduce future occurrence. It’s also important to create safe workplace environments so individuals involved in errors are not afraid to address future errors.2

But external factors aren’t the sole cause of medication errors. Psychosocial and cognitive factors can seriously impact the rates at which errors occur. Individuals who identify their own habits or knowledge gaps that might contribute to errors can take the next step: working on improving.

Definitions of “Medication Error”

To identify and prevent medication errors properly, having a clear, unambiguous definition would be ideal. Unfortunately, everyone seems to use similar—but different—definitions. Each person has a role and individual actions impact the team’s overall performance. Let’s compare a few definitions:

 

An error is a failure to complete a planned action as intended or the use of an incorrect plan of action to achieve a specific endpoint. Bad judgment, ignorance, or inattention might cause this type of error. A pharmacy situation might be when a technician fails to remove expired, very expensive medication and order new stock. When a new patient is admitted to the hospital and needs the medication immediately, the pharmacist hurries to process the order. Assuming that all medication in stock is in-date, the pharmacist approves an intravenous (IV) bag. At final verification, the pharmacist finally notices the medication’s expiration date. With no in-date stock, the pharmacist cannot send the IV. This mistake disrupts patient care. The pharmacy technician failed to keep the inventory in-date and the pharmacist assumed, failed to pay attention, and didn’t double check before proceeding.

 

An error is the enactment of a misconception due to incorrect information or part of a statement that is incorrect. An example in pharmacy might be when a doctor sends a new prescription with a higher-than-expected quantity, fails to update the prescription signatura (sig) or instructions, but tells the patient to take a higher dose. The puzzled pharmacist proceeds to process it. The insurance rejects the claim highlighting the calculated days-supply did not match the quantity indicated. While the pharmacist works on the prescription, the patient comes to the pharmacy to pick up her prescription. The pharmacist cannot contact the doctor who wrote the prescription and the doctor’s colleagues cannot confirm the prescription because they are unsure. The pharmacist decides to dispense a lower quantity per the old instructions so that the insurance will approve it. With the prescription now approved, the pharmacist dispenses the prescription but because the patient follows the doctor’s verbal directions, she runs out sooner than indicated on the prescription. She returns a few days later demanding more. The patient must now contact the insurance, the doctor, and the pharmacist to obtain the prescription that she needs. This could have been avoided if the doctor had noted that the patient would be taking the same drug at an increased dose.

 

An error is the departure from what is ethically acceptable or an incorrect result produced by automation. As healthcare systems increase their use of electronic health records, this problem is  increasing. Most systems are programmed to increase efficiency with the autofill function—meaning the computer will fill a field automatically based on the most common entry—which can increase avoidable errors. Too often, healthcare personnel blindly accept the computer-generated entry or calculations. This can result in a patient being given too much or too little drug and disrupt the quality of care.

 

In summary, medication errors occur in many ways (see Table 1). When a medication error occurs, it reduces the chances of achieving a desired outcome and the margin of safety associated with that outcome. Some medication errors result in adverse drug reactions but many do not. This is because not all adverse events cause adverse drug reactions.3 Many of us have made errors that serendipitously improved something. For example, a person making carrot soup may misread the words “1 garlic clove” and “1 teaspoon of cloves.” The soup will be different—and possibly better—than if the cook used garlic cloves. In medicine, however, errors are rarely “Happy Accidents” and we need to make every effort to reduce and eliminate them.

 

Table 1. Definition of Medication Errors

  • A misconception resulting from incorrect information
  • A wrong action attributable to bad judgment or ignorance or inattention
  • Departure from what is ethically acceptable
  • Inadvertent incorrectness
  • Part of a statement that is not correct
  • The occurrence of an incorrect result produced by a computer
  • Unintentional failures to act or plan (when it’s intentional, it’s a violation, not an error)

Source: Reference 3

Systemic Failures: Avoiding Blame

Many healthcare systems and providers now stress approaches that analyze errors as systemic failures. Systems, by nature, are interrelated units that work together toward the same goal. Most medication errors occur as a result of multiple, compounding events—or collapse of a faulty system—rather than an individual’s isolated act.4,5 It’s amazing how many times a serious error occurs because employees missed the opportunity to catch and rectify an error at multiple points in the patient’s care. Using a systems approach4,6

  • avoids assigning blame
  • explores relationships between various parts of the system, and
  • recognizes that cause and effect may be separated by space or time.

 

Many experts describe systemic failure using a Swiss cheese analogy. The holes in Swiss cheese represent the faults within a system. If an error passes through one of the holes in one slice of Swiss cheese, one would hope that the holes of the next slice of cheese won’t align, blocking the error. If the holes of the Swiss cheese slices all align, that medication error would slip through and reach the patient. Recognizing the placement of each slice—or the placement of each healthcare professional and that professional’s responsibility to be vigilant—can decrease the likeliness that a medication error will occur and it’s also key in identifying systemic failures.7,8

 

This Swiss cheese analogy can be applied to community pharmacy, where pharmacy staff establish multiple checkpoints during the filling process to ensure prescriptions are filled correctly (reviewing, scanning barcodes, tablet appearance, etc.). However, many patient safety cultures tend to look for explanatory causes for trouble and encourage blaming, criticizing, or silencing healthcare providers who make errors.4 For this reason, some experts refer to the individual who makes an error as the “second victim.” Lack of support from colleagues and supervisors can greatly affect involved health care providers’ ability to cope, leading to greater distress or protracted recovery.9

 

Fears of blame and punishment can deter individuals from reporting their errors, which can prevent creation of a culture of safety. Admitting one’s mistakes allows open discussion with peers and performance improvement experts can prevent further patient harm if they identify and fix the systemic “hole” causing the mistake.2,4 Let’s look at systems-based approaches first, and then examine why individual approaches are also critical.

 

QUALITY AND PERFORMANCE IMPROVEMENT APPROACHES

Various workplaces take different approaches to errors, but risk managers have proven certain approaches are more successful than others (see Table 2). The two most common approaches to analyzing medication errors are tracking and trending. Almost every workplace, whether it’s a healthcare facility or some other kind of business—requires employees to complete incident reports if they make an error. A responsible individual (usually someone designated as a quality or performance improvement specialist or a risk manager, although individuals may be interested in looking at their own errors) should look at incident reports over time to determine

  • What type of error or errors are most common
  • If a particular drug or product is involved in multiple incidents and why
  • The time of day or workload volume when the error occurred
  • The individual or individuals involved

 

This amounts to a type of detective work, in which the responsible party investigates medication errors individually and collectively to track and trend predisposing factors. If the data indicates that certain factors are trending (occurring more than once), the workplace can take action to prevent the error from happening again.10 Sometimes the action is as simple as heightening employees’ awareness that errors have occurred. Other times, the workplace might place a sign on a shelf indicating that a product is a look-alike or sound-alike product, mark bottles with bright colors to differentiate them, use TALL man lettering (see SIDEBAR), or conduct training so staff is better educated.

 

SIDEBAR; What is TALL man Lettering?

TALL man lettering is the practice of writing part of a drug's name in upper case letters to help distinguish sound-alike, look-alike drugs from one another. The goal is to differentiate drug names visually and avoid medication errors. The Office of Generic Drugs of the U.S. Food and Drug Administration (FDA) encourages manufacturers to use TALL man lettering labels. Many hospitals, clinics, and health care systems use TALL man lettering in their computerized order entry, automated dispensing machines, medication admission records, prescription labels, and drug product labels. Does your system use TALL man lettering? If not, should it?

 

The Institute for Safe Medication Practices creates a list of TALL man lettering for drug names. Most—but not all—of the drugs on the list are generic products. Find the list here: https://www.ismp.org/recommendations/tall-man-letters-list.

 

Here’s a snapshot from the center of the list:

 

Drug Name with TALL Man Letters Confused with
hydrALAZINE hydrOXYzine – HYDROmorphone
HYDROmorphone hydrOXYzine – hydrALAZINE
hydrOXYzine hydrALAZINEHYDROmorphone
medroxyPROGESTERone methylPREDNISolone – methylTESTOSTERone
methylPREDNISolone medroxyPROGESTERone – methylTESTOSTERone
methylTESTOSTERone medroxyPROGESTERone – methylPREDNISolone
mitoXANTRONE Not specified
niCARdipine NIFEdipine
NIFEdipine niCARdipine
prednisoLONE predniSONE
predniSONE prednisoLONE
risperiDONE rOPINIRole
rOPINIRole risperiDONE

 

Source: Reference 11

Table 2. Common Approaches to Medication Error-Related Performance Improvement

Term Definition
Tracking ·       The ability to assess performance; following the course or trail of someone or something, usually to find them or note their location. In pharmacy, this could include:
  • Product identification and verification, detection of and response to suspicion of illegitimate products
  • Record keeping located in pharmacies, distributers, and providers’ records
  • Patient data sharing to assist with medication reconciliation
  • Recording all variances on unusual incident reports
Trending ·       Monitoring the general direction in which something is developing or changing. In pharmacy, monitoring has led to expansion of the pharmacists’ role. Examples include vaccination administration, collaborative practice agreements in certain states, tobacco cessation programs, and point-of-care testing.

·       A method of estimating future costs of health services by reviewing past trends in cost and utilization of those services.

Root cause analysis ·       A full investigation of the causes of unexpected events followed by identification and implementation of appropriate and effective strategies to prevent similar occurrence in the future.

·       Asking “Why?” until it cannot be answered, often employing a “fishbone diagram” that looks at potential issues with materials, machines, methods, environment, measurements, and people.

·       It helps pharmacies take a process-driven, system-based approach to address errors.

Workplace re-engineering ·       Planned elimination, addition, or distribution of functions or duties in the workplace focused on innovative strategies to develop leaders, engage employees, and foster healthy workplace culture.

·       Is often influenced by excessive or insufficient labor, poor patient outcomes, or political or economic changes.

Disaster drill or mock code ·       An exercise or demonstration that tests the readiness and capacity of a hospital, a community, or other systems to respond to a possible public health emergency or other disaster.

Source: References 12, 13, 14, 15, 16, 19

 

In the event a serious error occurs, workplaces need to go beyond simple steps. One such step is to conduct a root cause analysis (RCA). RCA starts by reviewing what and how an event occurred, and expands the investigation to identify why it happened. Many organizations explain to their employees that RCA is the art of asking “Why” until no more questions beginning with “Why” are possible. Armed with that information, the RCA team can develop workable corrective measures that prevent future events of the type observed. RCA is not flawless, but it ensures that teams of people look at very serious errors and develop approaches that could prevent them in the future.20

 

Finally, errors are more likely to occur when unusual, unexpected, or unanticipated situations arise. For this reason, many organizations run disaster drills and observe them closely. In this way, they can identify areas where their systems are weak and implement corrective measures.21

 

Successful Programs

To create the best possible error prevention program, organizations can look at what has been proven to work. It’s clear that behavior-based programs create better outcomes than technology or any other approach.4 A leading researcher in pharmacy error identified six elements common to the most effective behavior-based programs (See Figure 1).4

 

Figure discussing six elements of performance improvement programs

Efforts that address the system and the individual jointly and individually are prudent. Consider a systemic safety measure: the widespread use of technology that is “smart.” Relying on technology and assuming it never fails may make some individuals become complacent and less vigilant until it is too late.4 Examples in community pharmacy are automated inventory systems and bar-code scanners. A person who enters data into a system—this would be an employee in the inventory management section in most pharmacies or healthcare systems—has a slight chance of entering an incorrect drug name. If no one catches the error, the last chance to prevent an error rests with the pharmacist who verifies that the tablet matches the description in the system before it is dispensed to the patient. The final check—a step that cannot and must not be automated—is an individual responsibility. Taking the extra seconds to verify the drug (while remembering that sometimes technology fails) can save a patient’s life from what could have been a deadly mistake.4

 

Many psychosocial factors also influence work performance. Work-as-imagined (work that is anticipated and described in official policies and procedures compiled by administrators or policy makers) and work-as-done (the way that employees actually accomplish work) are often quite different.22 Factors associated with the process of filling prescriptions are shown in Table 3.

 

 

Table 3. Psychosocial Factors that Influence Work Performance

  • Anxiety or depression
  • Changing workload
  • Competing tasks
  • Determination to “get the job done” despite barriers
  • Distraction or interruption
  • Hurrying
  • Insufficient decision support
  • Insufficient staffing
  • Knowledge gaps
  • Lack of experience
  • Lack of non-technical skills training (examples include communication, decision-making, reasoning, team work, time management)
  • Machinery or hardware that is difficult to operate
  • Perception that an error could lead to criminal charges
  • Rapidly changing or evolving roles
  • Use of “work-arounds” (shortcuts or approaches that differ from procedure) to overcome barriers
  • Vague or incomplete policy or procedure

 

Source: References 6, 22, 23, 24

 

The physical environment (inadequate illumination, environmental distractions, and noise), interruptions in workflow, facility design, technology, poorly designed labels, interpersonal relationships (e.g., number of interfaces with people and the level of stress and conflict caused by those interactions), and workload can adversely affect accuracy. 25,26,27

 

Many pharmacy employees associate high workload with increased error rates. They are often surprised to learn that low-workload conditions are more closely linked with errors than high-workload conditions. Consider a study conducted in 2000 that involved pharmacists, pharmacy technicians, and 21,672 prescriptions. Pharmacy employees made more process errors under low-workload conditions (11.2%) than under high-workload conditions (6.1%) and during periods when the workload trended downward in volume (at the start of a shift or after a break).28,29 In general, pharmacists were more vulnerable to mistakes when processing fewer than 15 prescriptions per hour than when processing more than 25 prescriptions per hour. (Author aside: We include these numbers because the study reported them, not as a hard and fast rule. We acknowledge that everyone has unique working habits, and some people can feel burned out processing fewer prescriptions than others.) A little bit of task tension (from perceived workload) seemed to result in fewer errors while filling prescriptions. However, there may be limits to the increases in task tension that would provide desirable results—too much stress and tension can become a problem. Overall, low levels of objective workload and subjective task tension were associated with more errors.26,30

 

Personal qualities can also play a role. Impulsivity, task frustration, fatigue, perceptual ability, concern for doing well, a lack of physical hardiness, and magnitude of personal effort expended can cause more errors to progress through the verification process unnoticed. Individuals should examine their task-related anxiety and overall job-related depression (a strong predictor of overall job stress often manifesting as constant complaining at work, impatience with coworkers, the need for “mental health days,” difficulty getting up on workdays, or physical illnesses) and address them if possible. Supervisors should examine employees’ task-related anxiety and overall job-related depression to help individuals cope; if not, anxiety and depression will affect job satisfaction and performance.4,22

 

Workplace support is also an important factor and the study mentioned earlier also demonstrated its importance. Pharmacists who had supervisors who they perceived as helping them set task goals and gain appropriate autonomy made fewer errors. Pharmacists who had supervisors who were overly autocratic (meaning domineering or overly involved in supervision) experienced tension that interfered with dispensing prescriptions accurately. Pharmacists who believed the number of breaks they receive was adequate to meet their needs made fewer process errors. 26 Later studies also confirm that poor leadership and insufficient support can adversely influence accuracy.22

 

ERRORS: WHAT WE KNOW

 

Errors are inevitable, but we must be able to recognize when we are prone to making errors to be able to limit them. Everyone has periods of increased errors—for instance during dramatic shifts in workload. Entering the pharmacy during peak hours can be stressful and predispose some individuals more than others to make errors they wouldn’t usually make. When we are flustered, our sense of logic escapes us momentarily.4,26

 

Some individuals make more frequent or predictable errors than others because of different cognitive styles. A classic study found that pharmacists whose cognitive styles include attention to details made fewer errors. It also found that about 12% of pharmacists have difficulty attending to details, and that 12% of pharmacists made 33% of errors.26 By using high-intensity task lights, exaggerated product label names (labels that are large and multicolored), NDC numbers, and specially designed devices for holding prescriptions at eye level during data entry, pharmacy staff who had difficulty being attentive to details made fewer errors.26 An 1999 incident monitoring study found poor communication and failure to check medical records when questions arose also contributed to errors.31 A more recent PRIORITIZE study conducted between September 2013 and November 2014 involving 500 North West London primary care clinicians noted the top three problems relating to medication errors in primary care were incomplete medication reconciliation during transitions of care, inadequate patient education about medication use, and poor discharge instructions.32 Clearly, healthcare providers have some communication problems.

 

A patient case in Pennsylvania illustrates the alarming consequences of poor communication between healthcare providers and fewer medication reconciliations. The patient was first hospitalized for uncontrolled blood pressure and acute kidney injury. At the time of discharge, one of her prescription medications was Norvasc® (a high blood pressure medication). The patient experienced worsening fatigue, slow movements, personality changes, and a ‘stoic’ facial expression with suboptimal blood pressure control. Soon after, she was hospitalized the second time for chest pain and underwent angioplasty. Several weeks later, she was diagnosed with anxiety and depression and was prescribed prescription medications for these conditions. The patient was admitted a third time to the emergency room after a fall with light-headedness and poor ambulation. It was only at the third visit when the medication reconciliation team realized her outpatient pharmacy accidentally dispensed Navane® (generic name as thiothixene, an antipsychotic) instead of Norvasc®. When thiothixene was discontinued, her clinical status improved. This preventable medication error occurred because the pharmacy staff and physician deemed the written prescription legible, when in actuality, it was not.8

 

Typically, people make mistakes or slips most frequently when new to the profession and lacking experience. A long period during which mistakes are rare follows. Eventually everyone develops unique work habits, and error rates tend to increase again, usually as bad habits develop.29,33

 

Finally, humans work on autopilot around 80% of the time. This means that 80% of the time, we don’t fully register what we are doing in our brain; we don’t engage with the task at hand and instead just go through the motions. Pharmacists also have an “inner pharmacist” who should kick in and take them out of autopilot mode when issues out of the ordinary arise.30,34,35 Often, when faced with errors after-the-fact, we clearly recall the circumstances under which they occurred because we wake up from our autopilot. We’ll talk more about autopiloting below.

 

How People Work

Workload in the pharmacy has been traditionally measured as the number of prescriptions dispensed per hour or day, or the number of prescriptions dispensed per pharmacist. Experts predict that the typical pharmacist’s workload has and will increase for two reasons:

  • An increase in demand from an aging population and
  • The addition of pharmacist-provided services (examples include medication therapy management, helping women select oral contraceptives in some states, and immunizations).

 

Instead of only focusing on the numbers, pharmacists, pharmacy technicians, and the organizations that employ them should focus on understanding the individual’s subjective experience of work demands. For pharmacists, verifying patient’s information, performing patient consultation and drug utilization reviews, and verifying prescriptions for accuracy can be demanding to the point that high workload negatively impacts performance. For technicians, similar factors—performing repetitive and mundane tasks, expanding roles, and high-risk assignments—may increase stress or create situations in which they must multi-task. Understanding that work is a process and not a series of discrete events can help maintain the “big picture.”30 That big picture is that pharmacists and pharmacy technicians must promote patient safety; dispensing to keep up with the pharmacy queue—the people who are in line or who have called in—is not prudent.36

 

Over the course of the day, filling many prescriptions is bound to cause a person go on autopilot—which is understandable. Humans are creatures of habit and routine. All humans work on autopilot around 80% of the time.4,34,35 Autopiloting occurs when the brain recognizes a situation and rapidly selects appropriate responses using familiar, predictable behavior context. The brain does this to preserve energy. Essentially, we perform most tasks reasonably well without thinking much about them. Many readers will sigh with recognition when they read this example: many people have left home on a non-work day to go someplace that’s in the general direction of work. They may be surprised to find themselves in their workplace’s parking lot. That’s autopilot. In the retail setting, pharmacy technicians and pharmacists autopilot the most when they are dealing with insurance coding and billing to third-party insurers. Autopiloting is usually safe.37

 

Our autopiloting should stop when we encounter stressful situations that are unfamiliar because our brains don’t know how to react appropriately in unfamiliar situations. In stressful situations, we tend to misapply familiar rules and knowledge. Intense emotion blocks out our sense of logic. In these situations, we have to remember to exercise mindfulness—taking a little bit of time away from the regular work stream to assess the situation calmly and proceed with a plan of action.4

 

It’s also crucial for each worker to know his or her own tendency to make errors and do what is necessary to refocus.4 However, all pharmacy employees must recognize that some people’s propensities and capabilities are hardwired.33 They cannot change their abilities and will approach work the same compulsive way, regardless of training.

 

Using technology to help us work is effective, but technology has limitations.38 Technology makes us lazy and unfamiliar with manual processes that have been automated. It is common for individuals to become complacent because we believe a machine designed for a specific purpose will complete the task correctly for us. We tend to trust that technology will work well all the time. It doesn’t.39 For instance, refilling a carousel cassette with the wrong medication will not prevent the machine from filling the prescription. This error can go undetected unless the pharmacist performs a final check before dispensing to the patient. This emphasizes the importance of the pharmacist’s individual responsibility as mentioned earlier.4,39

 

Self-improvement

While all of us prefer not to make errors, expecting an error rate of zero is unreasonable.4 Errors will happen. As noted above, some people make more errors than others, and a landmark study found that 12% of pharmacists made 30% of reported errors.26 Certainly, we all work with others who seem to make a disproportionate share of the workplace’s errors, and those who seem to be remarkably accurate. Where do you fall on the spectrum?

 

Examining your own error rate requires insight. This term—insight—is used most often in psychiatry and is defined as the patient’s awareness and understanding of the origins and meaning of his or her attitudes, feelings, and behavior, and disturbing symptoms.40 It means understanding of oneself. It has a slightly different meaning in the context of medication errors. In problem solving, it means the sudden perception of the appropriate relationships between things that results in a solution.41,42

 

Some people, and especially those who are error-prone, have poor insight. It may result from fixation, over-reliance on experience and past circumstances, rushing to solve a problem, or using the same approach over and over and expecting different results. Let’s look at each of these individually.

 

Fixation error refers to the tendency for the brain’s perceptual field to narrow and shorten in a crisis.43,44 When this happens, we develop a sometimes stymieing compulsion to fixate on the problem we think we can solve, and ignore almost everything else. During periods of fixation, time becomes distorted; minutes often seem longer than usual. In addition, the fixated individual may not hear input from others. Even the most skilled and experienced professionals can develop a fixation in periods of high stress.43,44

 

An example is that of a stalled car stuck on a level crossing as a distant train barrels toward it. The driver starts and restarts the engine, when the best way to save his life is to exit the car and run. In pharmacy, fixation errors occur when the provider concentrates on a single aspect of a case or problem to the detriment of other more relevant aspects. To break out of a fixation, individuals must be able to recognize the demand for a new approach to the problem and to produce a solution that works. Individuals who tend to fixate need to learn to43,44

  • Ask themselves what is different about the current problem
  • Heighten awareness of the people around them and listen
  • Invite others into the problem solving team to identify alternatives

 

Over-reliance on experience and past circumstances often occurs during emergencies. In this case, the individual tends to rely on past experience (even if it doesn’t apply in the current situation), and have difficulty abandoning assumptions based on that experience. In short, the person applies incident-specific experience to a situation that is probably much broader in nature. An example would be investigating why a patient who has asthma is experiencing exacerbations. If the pharmacist assumes the problem is treatment nonadherence when the actual problem is that the inhaler is faulty or requires skills like visual acuity or manual dexterity that the patient does not possess, the assumption can be deadly. In addition, during emergencies, individuals may have trouble recalling information accurately (elevated cortisol levels tend to change cognition and thinking). Often, using a cognitive aid like a checklist, decision tree, or an algorithm can help clarify thinking and lead to faster—and better—solutions.45

 

It’s interesting that many pharmacy staff members say, “I was rushing,” when they analyze errors, but few studies looked at or identified rushing as a cause. Rushing to problem-solve can increase the likelihood of error. An older study found that physicians linked 10% of errors to rushing or fatigue.31 Experts in medication error science also indicate that rushing contributes to error.46 An older study in Canada looked at a pilot program that transferred order entry responsibilities from pharmacists to pharmacy technicians. At the end of the study, the error rate had increased from 2.5% to 6%. Analysis indicated that technicians were rushing to enter orders, and re-training technicians to slow down and be mindful reduced the error rate to below the baseline level.47 Often, technicians may try to fill more quickly, or pharmacists rush the final verification step of dispensing as the customer line lengthens, and errors occur.

 

One area of growing interest is interruptions and interruption management.48,49 Interruptions have been shown to increase the medication error rate, and some studies suggest a technique called interruption management. They suggest using a “do not interrupt” sign or even a piece of clothing that warns people to stay away until the healthcare professional completes the task. They also recommend using a checklist for multistep processes. At this time, it’s unclear if these interventions help.48,49

 

Finally, many of us have fallen victim to a common dilemma: using the same approach over and over and expecting different results.4 Healthcare practitioners as a rule, do many tasks—even complicated ones—from memory rather than from following a checklist. Over time, and especially when we see our error rates beginning to climb upward, it’s important to look at our own work and consider ways in which we need to adjust or change (see Table 4). We cannot rely on what we did before. Over time, people change, workplaces change, and many of the problem’s underlying elements change.4 As we analyze errors, we must include what we’ve learned in the past, but be open to fresh approaches and ideas.

 

Table 4. Improving Your Own Accuracy

Do this…. And then do this…
Periodically review your errors and near-misses. Analyze errors to determine if you see a trend like confusing look-alike, sound-alike or spell-alike drugs.

Determine if you can take steps to reduce the likelihood of a similar error happening again.

Develop and use checklists if errors occur in multi-step processes.

Schedule visual and hearing exams more frequently as you age. Wear appropriate glasses or hearing aids at work.

Ask your employer for assistive devices (supplemental lighting, a magnifier, or a phone amplifier), or secure these yourself.

Solicit feedback from peers and supervisors about ways to reduce your own and others’ errors. Maintain a quiet, composed demeanor in the workplace.
Address workplace distractions as soon as you become aware of them. Reduce noise and clutter, improve lighting.
Understand technology’s limitations. Maintain your skills so that if technology fails, you can revert to the pre-technology work method.
Value relationships with coworkers and promote good organizational dynamics. Resolve disputes immediately, and retire grudges.

Provide feedback to coworkers constructively.

Address developing personal problems (alcohol abuse, marital discord) early.

 

Engage with your employer’s employee assistance program before your supervisor refers you.
Understand that some people make errors because they lack knowledge. Address your own knowledge gaps, and promote a culture of learning.
Avoid relying on “workplace re-engineering” or “work task design” to prevent errors; these may fail as the workplace composition and focus changes. Learn to engage and listen to your “inner pharmacist” or “inner technician” when something is out of the ordinary.

 

 

When we discuss medication errors, it’s critical to talk about data entry errors because they represent about 25% of all medication errors.25 The pharmacy has many repetitive tasks like data entry or filling prescriptions. Many of these tasks can be completed without conscious awareness. This ‘autopilot’ function contributes to data entry errors like misspellings or errors recorded on the patient’s profile. The vast majority of data entry errors are inconsequential, but some are dangerous.25

 

Many factors could impact the cognitive system directly. Pharmacists and pharmacy technicians can take some simple steps to increase accuracy in the pharmacy. Figure 2 suggests a few, but individuals will find the best solutions are those they develop themselves and tailor to their own habits and circumstances.

 

Figure discussing four error prevention techniques in the pharmacy

 

Reducing Workplace Turbulence

Workplace turbulence occurs when something causes discomfort or decreases workplace stability. Some things that cause workplace turbulence include poor temperature control (it’s either too hot or too cold), noise, clutter, uncertainty, or working with people who have different styles or personalities that are abrasive to you. These things affect accuracy and productivity. If workplace distractions are the problem, making small changes to decrease turbulence can make large differences.29,33

 

If the problems are environmental, ask the appropriate person to help resolve them. Establishing good relationships with the people who provide environmental support—people in building supervision, maintenance, and housekeeping—is imperative. They can often help adjust the ambient temperature or reduce clutter. Learning to work with instead of against or parallel to coworkers and supervisors can improve the environment.4 The key is telling your supervisor how you best hear constructive criticism and delivering constructive criticism to others in a positive way—and in the way they receive it best.

 

Finally, be aware of when you are fatigued or unable to perform at your peak and enlist coworkers' help by asking them to monitor your work.29,33

 

Poka-Yoke

Since the 1960s, many industries have adopted the principles of poka-yoke, also called “mistake-proofing,” to prevent errors.50 Poka-yoke is a systems approach, but unlike many systems approaches, the people closest to the work (not administrators or policy makers) propose the action. Defined broadly, poka-yoke refers to any behavior-shaping constraint in a process that prevents faulty behaviors by the worker. An industrial engineer at Toyota developed this concept, and it encourages workplaces to look at common mistakes and develop processes that make it impossible for workers to make the mistake in the future. Basically, it’s defensive workplace design. It depends on involving the people closest to the work to identify what to mistake-proof and develop ideas to prevent very specific mistakes. In pharmacies, four poka-yoke principles are used often, and can be applied in many more areas.50-52

 

First, workplace managers need to empower employees to pause or even stop the work process entirely if they believe that an error is in process.29 Employees need to be able to ask four questions respectfully:

  • Did we do everything?
  • Did we do everything right?
  • Does it look, sound and feel right?
  • Are these our usual work conditions?

 

Next, everyone in the pharmacy community from manufacturers to distributors to providers who work in direct patient care need to make it easier for people to do the right thing than the wrong thing. A short example can clarify this principle. Years ago at the National Cancer Institute, a collaborating company was developing a new monoclonal antibody (MAB). The MAB was lyophilized and came in a fairly large multidose vial. It needed to be reconstituted with 20 mL of a specific diluent. The manufacturer provided the MAB with a vial of the diluent that contained 30 mL. The astute reader will see the potential for error. In many cases, pharmacists and pharmacy technicians who worked in investigational drug preparation looked at the package, and simply transferred the diluent—all 30 mL of it—into the larger vial. The resultant solution was an incorrect dose. Can you see why? Diluting a 400 mg vial with 20 mL creates a 20 mg/mL solution. Using 30 mL creates a 13.33 mg/mL solution. After investigational drug employees identified and reported this error several times, and the NCI reported it to the manufacturer, the simple poka-yoke fix was implemented. Although it took quite some time to implement the change, eventually the manufacturer packaged the MAB with a vial of diluent that had the correct amount needed in it—20 mL.

 

People who work in pharmacy in any capacity can make it easier to do the right thing than the wrong thing in numerous ways. Let’s discuss four of them.

  • Putting items that will always be used together in that same container, and making sure that the items that are assembled are the correct sizes or doses or quantities, is kitting at work. It results in fewer missing parts, and it also speeds your process. Some experts estimate that it can cut errors by as much as 80%.53 The solution noted above is an example of kitting. Other examples of kitting are creating bowel evacuation kits for patients having colonoscopies, or assembling packages of items that are frequently prescribed together for specific procedures or treatments.
  • Keying simply means that a process can’t be started without a key or tool of some sort. The requirement to remove your ATM card before receiving cash is an application of this principle so people don’t leave their cards in the machine. An example in the pharmacy is a computer that requires the user to insert an ID card to start the system. This increases accuracy and prevents users from signing in early in the day, walking away from the computer, and allowing others to operate under an incorrect sign-in code. Another example of a type of keying is moving pseudoephedrine to behind the counter in the pharmacy. Adding that step—requiring customers to sign for pseudoephedrine and limiting quantities—ensures there is a check in the process. States that have implemented this step have decreased the amount of pseudoephedrine diverted to methamphetamine production significantly.
  • Interlocking uses simple mechanisms so that parts will only fit with other appropriate pieces. These are simple, low cost devices that prevent parts from being assembled incorrectly. An everyday example of poka-yoke for someone who always forgets or loses his keys is to place the keys in the shoes he will wear tomorrow. An example in pharmacy might be providing drugs meant to be administered intrathecally in a device that cannot attach to any intravenous equipment.
  • Tell-tales let you know when you have made an error. Barcoding is a type of telltale. When you scan a barcode and it doesn’t match the barcode on the actual order, it sends you an alert that you’ve made an error.

 

The last poke yoke principle we’ll cover is this: Make mistakes obvious to workers immediately and discretely so they can make on-the-spot corrections, and allow people to take corrective actions or stop the work flow before irreversible damage is done. This small kindness brings errors to the error-maker’s attention, and allows immediate learning.

 

CONCLUSION

Despite our best intentions, some errors escape the confines of the pharmacy. Randomly checking completed work that has apparently passed verification sometimes identifies problem areas. But, some errors are just that—unfortunate events that could not be anticipated and occurred due to a confluence of factors. Even though reaching a medication error rate of zero is improbable, we should still make efforts to acknowledge our professional responsibility in our own work habits. Creating solutions tailored to our habits and circumstances can help reduce error rates and encourage a focus on a workplace culture of patient safety—not the number of prescriptions filled—as the big picture in pharmacy.

 

 

Pharmacist Post Test (for viewing only)

LEARNING OBJECTIVES
After participating in this activity, pharmacists and pharmacy technicians will be able to:
1. Discuss the difference between systemic approaches to medication errors and individual (personal) responsibilities for medication errors
2. Outline various causes for medications errors that can be traced back to individuals
3. Discuss ways in which peoples’ unique work habits influence their propensity to make errors
4. Identify methods to reduce an individual’s medication error rate and apply them appropriately

1. Which of these can INCREASE the chance of making errors?
A. Labeling of common look-alike, sound-alike drugs on shelves
B. Working on autopilot to perform tasks that are very routine
C. Working during a dramatic increase or decrease in workload

2. Which is an example of individual responsibility for medication errors?
A. A hospital administration implements autofill functions in the computer software to improve efficiency
B. A pharmacist provides the final check of a prescription after the prescription bottle comes out of the carousel
C. A manufacturer packages an intramuscular injection and its diluent in proper quantities in the same box

3. Eloise is a pharmacist at your hospital pharmacy. She is a reliable employee and one of the most skilled and experienced members of the pharmacy team. She has good recollection, even in stressful situations, but she tends to fixate when dealing with emergencies. If this situation occurs, which of the following should she perform FIRST?
A. Isolate herself from the people around her so she can think
B. Try to rectify the problem based on her past experiences
C. Take a moment to ask herself what’s different about this problem

4. What have studies of errors in healthcare found to be TRUE?
A. Eventually everyone’s error rate increases after a period of time working in their profession.
B. Addressing the system and individual jointly and individually is useless for analyzing errors.
C. Technology creates better outcomes than behavior-based programs.

5. What was the cause of the medication error in the Pennsylvania patient case described in this CE activity?
A. Poor communication
B. Bad work habits
B. Autopiloting

6. Which one of these is an example of how can individuals can improve their personal medication error rates?
A. Using the same approach over and over for different situations for consistency
B. Pointing out other team members’ mistakes so others will not do the same thing
C. Applying what you know works well while being open to fresh approaches and ideas

7. Mike is a pharmacy technician who works in a community retail pharmacy. He prides himself on being a people-person and receiving good feedback from patients. Last month while chatting with customers, he accidentally reconstituted an antibiotic medication with too much diluent. The pharmacist dispensed it and the patient now has a resistant infection due to receiving suboptimal treatment. As the pharmacist filled out an incident report, he told ML to stop talking with the customers and focus on his work. Since then, ML has become quieter. Patients have noticed his change in demeanor and brought it up with the pharmacist. What do you think the pharmacist should do next?
A. Tell patients that nothing’s wrong with Mike. He’s just focusing on his work because he made an error when he was distracted previously.
B. Ask Mike if he has a moment to talk about last week’s incident, apologize, to him and ask how Mike would prefer to hear criticism in the future.
C. Disregard their concerns – Mike was a chatter box who needed to learn how to limit his talking sooner rather than later.

8. Which of the following statements describe how the workload in the pharmacy should be measured?
A. The number of prescriptions per hour or day
B. The individual’s subjective experience of work demands
C. The number of prescriptions per pharmacist

9. CJ is an experienced pharmacist. With a growing number of tasks, CJ has been struggling to stay afloat. On a busy afternoon, CJ administered multiple immunizations and answered dozens of phone calls. The wait time was longer and longer. CJ made a list of his remaining tasks. He decides to rush through prescriptions to clear the queue. Which of the following could contribute to increased risk of medication error and is within CJ’s control?
A. The growing list of tasks to be done as a pharmacist
B. A particularly busy work day or time of day at the pharmacy
C. Rushing without addressing ways to readjust to accommodate for new tasks

10. Which factors help reduce medication error?
A. Leaving conflicts in the workplace unresolved and unacknowledged
B. Avoiding personal problems until they become a problem at the work place
C. Creating a safe environment for individuals involved in the error

11. Which of the following is a cognitive factor that influences workplace performance?
A. Changing workload
B. Insufficient staffing
C. Attention to detail

12. Which is an example of a SYSTEMIC approach that would increase medication errors?
A. A pharmacist performs final verification of a prescription after final packaging
B. The pharmacy implements automated inventory systems, autofill, and bar code scanners
C. A technician carefully checks for expiration dates and disposes medication accordingly

13. Which of the following would INCREASE an individual’s medication error rate?
A. Relying on technology whenever possible and utilize more “smart technology”
B. Maintaining skills so that if technology fails, you can revert to manual work methods
C. Wearing appropriate glasses, secure assistive devices or hearing aids at work.

14. Which of the following will INCREASE medication errors that are traced back to individuals?
A. Employees routinely examine their task-related anxiety and job-related depression
B. The pharmacy has poor leadership and insufficient support for employees
C. Pharmacy employees believe the number of breaks they receive are adequate

Pharmacy Technician Post Test (for viewing only)

LEARNING OBJECTIVES
After participating in this activity, pharmacists and pharmacy technicians will be able to:
1. Discuss the difference between systemic approaches to medication errors and individual (personal) responsibilities for medication errors
2. Outline various causes for medications errors that can be traced back to individuals
3. Discuss ways in which peoples’ unique work habits influence their propensity to make errors
4. Identify methods to reduce an individual’s medication error rate and apply them appropriately

1. Which of these can INCREASE the chance of making errors?
A. Labeling of common look-alike, sound-alike drugs on shelves
B. Working on autopilot to perform tasks that are very routine
C. Working during a dramatic increase or decrease in workload

2. Which is an example of individual responsibility for medication errors?
A. A hospital administration implements autofill functions in the computer software to improve efficiency
B. A pharmacist provides the final check of a prescription after the prescription bottle comes out of the carousel
C. A manufacturer packages an intramuscular injection and its diluent in proper quantities in the same box

3. Eloise is a pharmacist at your hospital pharmacy. She is a reliable employee and one of the most skilled and experienced members of the pharmacy team. She has good recollection, even in stressful situations, but she tends to fixate when dealing with emergencies. If this situation occurs, which of the following should she perform FIRST?
A. Isolate herself from the people around her so she can think
B. Try to rectify the problem based on her past experiences
C. Take a moment to ask herself what’s different about this problem

4. What have studies of errors in healthcare found to be TRUE?
A. Eventually everyone’s error rate increases after a period of time working in their profession.
B. Addressing the system and individual jointly and individually is useless for analyzing errors.
C. Technology creates better outcomes than behavior-based programs.

5. What was the cause of the medication error in the Pennsylvania patient case described in this CE activity?
A. Poor communication
B. Bad work habits
B. Autopiloting

6. Which one of these is an example of how can individuals can improve their personal medication error rates?
A. Using the same approach over and over for different situations for consistency
B. Pointing out other team members’ mistakes so others will not do the same thing
C. Applying what you know works well while being open to fresh approaches and ideas

7. Mike is a pharmacy technician who works in a community retail pharmacy. He prides himself on being a people-person and receiving good feedback from patients. Last month while chatting with customers, he accidentally reconstituted an antibiotic medication with too much diluent. The pharmacist dispensed it and the patient now has a resistant infection due to receiving suboptimal treatment. As the pharmacist filled out an incident report, he told ML to stop talking with the customers and focus on his work. Since then, ML has become quieter. Patients have noticed his change in demeanor and brought it up with the pharmacist. What do you think the pharmacist should do next?
A. Tell patients that nothing’s wrong with Mike. He’s just focusing on his work because he made an error when he was distracted previously.
B. Ask Mike if he has a moment to talk about last week’s incident, apologize, to him and ask how Mike would prefer to hear criticism in the future.
C. Disregard their concerns – Mike was a chatter box who needed to learn how to limit his talking sooner rather than later.

8. Which of the following statements describe how the workload in the pharmacy should be measured?
A. The number of prescriptions per hour or day
B. The individual’s subjective experience of work demands
C. The number of prescriptions per pharmacist

9. CJ is an experienced pharmacist. With a growing number of tasks, CJ has been struggling to stay afloat. On a busy afternoon, CJ administered multiple immunizations and answered dozens of phone calls. The wait time was longer and longer. CJ made a list of his remaining tasks. He decides to rush through prescriptions to clear the queue. Which of the following could contribute to increased risk of medication error and is within CJ’s control?
A. The growing list of tasks to be done as a pharmacist
B. A particularly busy work day or time of day at the pharmacy
C. Rushing without addressing ways to readjust to accommodate for new tasks

10. Which factors help reduce medication error?
A. Leaving conflicts in the workplace unresolved and unacknowledged
B. Avoiding personal problems until they become a problem at the work place
C. Creating a safe environment for individuals involved in the error

11. Which of the following is a cognitive factor that influences workplace performance?
A. Changing workload
B. Insufficient staffing
C. Attention to detail

12. Which is an example of a SYSTEMIC approach that would increase medication errors?
A. A pharmacist performs final verification of a prescription after final packaging
B. The pharmacy implements automated inventory systems, autofill, and bar code scanners
C. A technician carefully checks for expiration dates and disposes medication accordingly

13. Which of the following would INCREASE an individual’s medication error rate?
A. Relying on technology whenever possible and utilize more “smart technology”
B. Maintaining skills so that if technology fails, you can revert to manual work methods
C. Wearing appropriate glasses, secure assistive devices or hearing aids at work.

14. Which of the following will INCREASE medication errors that are traced back to individuals?
A. Employees routinely examine their task-related anxiety and job-related depression
B. The pharmacy has poor leadership and insufficient support for employees
C. Pharmacy employees believe the number of breaks they receive are adequate

References

Full List of References

 

References

 

  1. Anderson JG, Abrahamson K. Your health care may kill you: medical errors. Building Capacity for Health Informatics in the Future. 234:13-17. DOI 10.3233/978-1-61499-742-9-13. Accessed December 27, 2022. http://ebooks.iospress.nl/publication/46132.
  2. Rogers EE, Griffin E, Carnie W, et al. A just culture approach to managing medication errors. Hosp Pharm. 2017;52(4):308-315.
  3. Aronson, J. (2019). Medication errors: definitions and classification. Accessed December 27, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723196/
  4. Grasha AF. Into the abyss: seven principles for identifying the causes of and preventing human erros in complex systems. Am J Health-Syst Pharm. 2000:57:544-564.
  5. Hodgson BB, Kizior RJ. Appendix L. In: Hodgson BB, Kizior RJ, Saunders Nursing Drug Handbook 2013. 1st edition. St. Louis, Missouri, Saunders/Elsevier; 2012:1290.
  6. Vosper H, Lim R, Knight C, et al. Considering human factors and developing systems- thinking behaviours to ensure patient safety. Clinical Pharmacist. 2018,10:2. Accessed December 27, 2022. https://dspace.lboro.ac.uk/dspace-jspui/bitstream/2134/28474/3/Hignett_Vosper%202018%20ACCEPTED%20%20pharmaceutical-journal.com.pdf
  7. Rosen RK. Medication errors: a 21st-century perspective. Proceedings (Bayl Univ. Med Cent). 2004;17(4):464-467;discussion 467-468.
  8. da Silva BA, Krishnamurthy M. The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect. 2016;6(4):31758.
  9. Quillivan RR, Burlison JD, Browne EK, et al. Patient safety culture and the second victim phenomenon: connecting culture to staff distress in nurses. Jt Comm J Qual Patient Saf. 2016:42(8):377-86.
  10. Rogers, Erin, et al. A Just Culture Approach to Managing Medication Errors. National Center for Biotechnology Information, April 2017. Accessed December 27, 2022. www.ncbi.nlm.nih.gov/pmc/articles/PMC5424837/
  11. Institute for Safe Medication Practices. Look-alike drug names with recommended tall man letters. Accessed December 27, 2022.Available at https://www.ismp.org/recommendations/tall-man-letters-list
  12. “Emergency Preparedness: 3 Steps to Prepare Your Pharmacy.” PBA Health, 12 Mar. 2018, Accessed December 27, 2022. Emergency Preparedness: 3 Steps to Prepare Your Pharmacy (pbahealth.com)
  13. Reorganization. Defined Term. Accessed December 27, 2022. https://definedterm.com/reorganization
  14. Root Cause Analysis Workbook for Community/Ambulatory Pharmacy. Institute For Safe Medication Practices. Accessed December 27, 2022. www.ismp.org/resources/root-cause-analysis-workbook-community-ambulatory
  15. Schwartz, Heidi. Re-Engineering the Workplace For Employee Wellness. January 26, 2015. Facility Executive Magazine. Accessed December 27, 2022. https://facilityexecutive.com/2015/01/employers-will-be-challenged-to-re-engineer-the-workplace-attract-and-retain-people/
  16. “Tracking.” Defined Term. Accessed December 27, 2022. https://definedterm.com/tracking

 

  1. Benedetto AR. Six Sigma: not for the faint of heart. Radiol Manage. 2003;25(2):40-53.
  2. Rodziewicz TL, Houseman B, Hipskind JE. Medical Error Reduction and Prevention. In: StatPearls. Treasure Island (FL): StatPearls Publishing; December 4, 2022.
  3. “Trending.” Defined Term. Accessed December 27, 2022. https://definedterm.com/trending
  4. Agency for Healthcare Research and Quality. Root cause analysis. Accessed December 27, 2022. https://psnet.ahrq.gov/primers/primer/10/root-cause-analysis
  5. “Lessons We Don't Learn: A Study of the Lessons of Disasters, Why We Repeat Them, and How We Can Learn Them.” January 15, 2015. HOMELAND SECURITY AFFAIRS. Accessed December 27, 2022. www.hsaj.org/articles/167
  6. Sutherland A, Ashcroft DM, Phipps DL. Exploring the human factors of prescribing errors in paediatric intensive care units. Arch Dis Child. 2019;104(6):588-595. doi:10.1136/archdischild-2018-315981
  7. Bhangu A, Bhangu S, Stevenson J, Bowley DM. Lessons for surgeons in the final moments of Air France Flight 447. World J Surg. 2013;37(6):1185-1192.
  8. Croft H, Nesbitt K, Rasiah R, Levett-Jones T, Gilligan C. Safe dispensing in community pharmacies: applying the software, hardware, environment and liveware (SHEL) model. Pharmaceutical J. 2017;9(7): DOI: 10.1211/CP.2017.20202919. Accessed December 27, 2022. https://www.pharmaceutical-journal.com/research/safe-dispensing-in-community-pharmacies-applying-the-software-hardware-environment-and-liveware-shell-model/20202919.article
  9. Grasha AF, Schell K. Psychosocial factors, workload, and human error in a simulated pharmacy dispensing task. Perceptual Motor Skills. 2001;92:53-71.
  10. Grasha AF. Understanding medication errors: a cognitive systems approach. Medscape. May 14, 2001. Accessed December 27, 2022. https://www.medscape.org/viewarticle/418538
  11. Grasha AF, Reilley S, Schell K, Tranum D, Filburn J. A cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction. Cincinnati, Ohio: University of Cincinnati,2000, Cognitive Systems Lab Report 062100-R.
  12. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
  13. Barry R, Murcko AC, Brubaker CE. The Six Sigma Book for Healthcare. Ann Arbor, MI: Chicago Health Administration Press; 2002:19-43.
  14. Grasha AF. Misconceptions about pharmacy workload. Can Pharmaceut J. 2001;134(4):26-35.
  15. Bhasale AL, Miller GC, Reid SE, Britt HC. Analysing potential harm in Australian general practice: an incident-monitoring study. Med J Aust. 1999;170(6):287-288.
  16. Tudor CL, Papachristou N, Gallagher J, et al. Identifications of priorities for improvement of medication safety in primary care: a PRIORTIZE study. BMC Fam Pract. 2016;17(1):160.
  17. Bogner MS. Misadventures in Healthcare. Mahwah, NJ: Lawrence Erlbaum Associates; 2004:1-186
  18. Ashcraft MH. Human memory and cognition (2nd ed.). New York: Harper Collins, 1994.
  19. Anderson JR. Learning and memory: An integrated approach. New York: John Wiley & Sons, 1995.
  20. Chui MA, Mott DA. Community pharmacists’ subjective workload and perceived task performance: a human factors approach. J Am Pharm Assoc (2003). 2012;52(6):e153-e160.
  21. Vatansever D, Menon DK, Stamatakis EA. Default mode contributions to automated information processing. PNAS. 2017;114(48):12821-12826.
  22. Gouraud J, Delorme A, Berberian B. Autopilot, mind wandering, and the out of the loop performance problem. Front Neurosci. 2017;11:541.
  23. Casey S. Set Phasers on Stun: And Other True Tales of Design, Technology and Human Error. Santa Barbara, CA: Aegean; 1998.
  24. “Insight,” The Free Dictionary. Accessed December 27, 2022. https://medical-dictionary.thefreedictionary.com/insight
  25. Psychestudy. Insight Learning. Accessed December 27, 2022. https://www.psychestudy.com/behavioral/learning-memory/insight-learning
  26. How to Detect Insight Moments in Problem Solving Experiments. Accessed December 27, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854655/
  27. Fioratou E, Flin R, Glavin R. No simple fix for fixation errors: cognitive processes and their clinical applications. Anaesthesia. 2010;65(1):61-69.
  28. Leslie I. How mistakes can save lives: one man’s mission to revolutionise the NHS. June 4, 2014. Accessed December 27, 2022. https://www.newstatesman.com/2014/05/how-mistakes-can-save-lives
  29. Jenkins B. Cognitive aids: time for a change? Anaesthesia. 2014;69:655–668.
  30. Grasha AF. Tools for the reflective practitioner: Using self-monitoring, personal feedback and goal setting to reduce error. Health Notes Qual Assur. 2002;19-24.
  31. Tierney M, McLurg D, Macmillan C. Transferring medication order entry from pharmacists to pharmacy technicians. JCPH. 1999;52(4):240-243.
  32. Lapkin S, Levett-Jones T, Chenoweth L, Johnson M. The effectiveness of interventions designed to reduce medication administration errors: a synthesis of findings from systematic reviews. J Nurs Manag. 2016;24(7):845-858. doi:10.1111/jonm.12390
  33. Castro-Rodríguez C, De Lucas-Volle S, González-Roca I, Diaz-Redondo A, Mora-Capín A, Marañón R. Professionals' Perception of a Strategy to Avoid Interruptions During Medication Handling. J Patient Saf. 2023;19(1):29-35. doi:10.1097/PTS.0000000000001082
  34. Soliman-Junior, J., Tzortzopoulos, P., and Kagioglou, M. 2020. “Exploring Mistakeproofing in Healthcare Design.” In: Tommelein, I.D. and Daniel, E. (eds.). Proc. 28th Annual Conference of the International Group for Lean Construction (IGLC28), Berkeley, California, USA, doi.org/10.24928/2020/0034
  35. Van Scyoc K. Process safety improvement--quality and target zero. J Hazard Mater. 2008;159(1):42-48.
  36. Kumar S, Steinebach M. Eliminating US hospital medical errors. Int J Health Care Qual Assur. 2008;21(5):444-471.
  37. China Manufacturing Consultants. 6 Poka Yoke (mistake proofing) techniques that most factories overlook. Accessed December 22, 2022. http://www.cmc-consultants.com/blog/6-poka-yoke-mistake-proofing-techniques-that-most-factories-overlook

 

 

Patient Safety: Medication Refusal: Understanding the Why “They Just Say No”

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists will be able to

Recognize and define types and leading causes of treatment/medication refusal
Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
Determine treatment alternatives for patients with dietary, religious, or other restrictions
Identify and implement key components of a medication refusal protocol

    After completing this application-based continuing education activity, pharmacy technicians will be able to

    Recognize and define types and leading causes of treatment/medication refusal
    Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
    Determine treatment alternatives for patients with dietary, religious, or other restrictions
    Identify and implement key components of a medication refusal protocol

     

    Release Date: October 17, 2023

    Expiration Date: October 15, 2026

    Course Fee

    Pharmacists: $7

    Pharmacy Technicians: $4

    There is no grant funding for this CE activity

    ACPE UANs

    Pharmacist: 0009-0000-23-047-H05-P

    Pharmacy Technician: 0009-0000-23-047-H05-T

    Session Codes

    Pharmacist:  20YC80-TRX39

    Pharmacy Technician:  20YC80-XRT42

    Accreditation Hours

    2.0 hours of CE

    Accreditation Statements

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-047-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

     

    Disclosure of Discussions of Off-label and Investigational Drug Use

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Faculty

    Danielle Haskins, PharmD
    CVS Pharmacy Manager
    Santee, CA

     

    Ming May Zhang, PharmD Candidate 2022
    University of Connecticut School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    Danielle Haskins and Ming May Zhang  do not have any financial relationships with ineligibile companies.

     

    ABSTRACT

    Based on the principle of informed consent, competent patients always
    have the right to refuse medical treatment. Patients may refuse treatment
    for a variety of reasons, including dietary restrictions, religious reasons, medical
    misconceptions, a desire to avoid adverse effects, and mistrust of the medical
    team. Patient refusals can create serious dilemmas in the healthcare setting. On
    the one hand, clinicians have an ethical and legal obligation to honor patient autonomy.
    On the other hand, a patient’s refusal of treatment often leads to adverse
    medical outcomes, resulting in harm to the patient. Healthcare
    professionals should search for acceptable treatment alternatives that honor patients’
    wishes while meeting their medical needs. Every institution—whether in
    the community, long-term care, or inpatient setting—should have a protocol to
    guide and standardize the approach to managing treatment refusals. In complex
    cases, it may be beneficial to use expert ethics consultations.

    CONTENT

    Content

    ONLY PDF version is Available for this CE

     

     

    Pharmacist Post Test (for viewing only)

    Medication Refusal: Understanding the Why "They Just Say No"
    After participating in this activity, pharmacists and pharmacy technicians will be able to
    1. Recognize and define types and leading causes of treatment/medication refusal
    2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
    3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
    4. Identify and implement key components of a medication refusal protocol

    1. Which of the following is an example of ACTIVE medication refusal?
    a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
    b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
    c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

    2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
    a. Gelatin
    b. Peanut oil
    c. Mannitol

    3. Which of the following best describes motivational interviewing?
    a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
    b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
    c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

    4. Which of the following statements is FALSE about the practice of covert medication?
    a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
    b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
    c. It may be better received than more aggressive methods, such as forced injections.

    5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
    a. Dietary restriction
    b. Medical misconception
    c. Mistrust of the medical team

    6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
    a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
    b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
    c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

    7. Why might an ethics consultation be useful in certain instances of treatment refusal?
    a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
    b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
    c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

    8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
    a. Beneficence
    b. Primum non nocere
    c. Autonomy

    9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
    a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
    b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
    c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

    10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
    a. Intentional non-adherence
    b. Unintentional non-adherence
    c. Passive refusal

    11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
    a. Religious refusal
    b. Lack of belief in the medications’ effect
    c. Mistrust of the medical provider

    12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
    a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
    b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
    c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

    Pharmacy Technician Post Test (for viewing only)

    Medication Refusal: Understanding the Why "They Just Say No"
    After participating in this activity, pharmacists and pharmacy technicians will be able to
    1. Recognize and define types and leading causes of treatment/medication refusal
    2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
    3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
    4. Identify and implement key components of a medication refusal protocol

    1. Which of the following is an example of ACTIVE medication refusal?
    a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
    b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
    c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

    2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
    a. Gelatin
    b. Peanut oil
    c. Mannitol

    3. Which of the following best describes motivational interviewing?
    a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
    b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
    c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

    4. Which of the following statements is FALSE about the practice of covert medication?
    a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
    b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
    c. It may be better received than more aggressive methods, such as forced injections.

    5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
    a. Dietary restriction
    b. Medical misconception
    c. Mistrust of the medical team

    6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
    a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
    b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
    c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

    7. Why might an ethics consultation be useful in certain instances of treatment refusal?
    a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
    b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
    c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

    8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
    a. Beneficence
    b. Primum non nocere
    c. Autonomy

    9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
    a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
    b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
    c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

    10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
    a. Intentional non-adherence
    b. Unintentional non-adherence
    c. Passive refusal

    11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
    a. Religious refusal
    b. Lack of belief in the medications’ effect
    c. Mistrust of the medical provider

    12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
    a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
    b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
    c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

    References

    Full List of References

    References

       

      These can be found on the pdf version of the CE

      Patient Safety: Seven Secrets for Patient Safety with Dietary Supplements

      Learning Objectives

       

      After completing this application-based continuing education activity, pharmacists will be able to

      ·       Discuss the importance of knowing about a patient’s dietary supplement usage
      ·       Identify commonly used dietary supplements, their regulation, and the value of certification
      ·       Recognize potential medication-dietary supplement interactions
      ·       Demonstrate the ability to locate different sources of information about dietary supplements

      After completing this application-based continuing education activity, pharmacy technicians will be able to

      ·       Discuss the importance of knowing about a patient’s dietary supplement usage
      ·       Identify commonly used dietary supplements, their regulation, and the value of certification
      ·       Recognize potential medication-dietary supplement interactions
      ·       Recognize the need for pharmacist counseling when a patient is taking a dietary supplement

      Image of a dinner plate filled with various colored medication capsules.

       

      Release Date: January 16, 2023

      Expiration Date: January 16, 2026

      Course Fee

      Pharmacists: $7

      Pharmacy Technicians: $4

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-001-H05-P

      Pharmacy Technician: 0009-0000-23-001-H05-T

      Session Codes

      Pharmacist:  23YC01-FKE24

      Pharmacy Technician:  23YC01-EFK68

      Accreditation Hours

      2.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-001-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Jennifer Salvon, RPh
      Clinical Pharmacist
      Mercy Medical Center

      Springfield, MA

      Adjunct Faculty Member
      University of Connecticut School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Jennifer Salvon does not have any relationships with ineligible companies and therefore has nothing to disclose.

       

      ABSTRACT

      Consumer consumption of dietary supplements is at an all-time high. Available products number in the tens of thousands, generating millions in annual spending. Increasing interest in overall health and wellness, preventive medicine, and immune function contribute to the rise in usage. It is a common misconception that dietary supplements are safe because they are “natural.”
      Ingestion of dietary supplements poses serious health risks including adverse reactions, drug interactions, and toxicity. Adulterated, mislabeled, and contaminated products exist in the marketplace, further increasing consumer risk. Existing federal regulation and oversight for supplements differs from prescription and over-the-counter medications, occurring primarily on a post-marketing basis. Self-reporting by consumers, healthcare professionals, and industry personnel identifies these issues. Patients often omit dietary supplements from medication histories, leaving healthcare professionals unaware that patients are using them. While misinformation abounds on the Internet, many online clinically-backed sources exist.

      CONTENT

      Content

      Introduction

       

      Consuming natural substances to produce a desired effect on the body dates back thousands of years to ancient Egypt, Rome, China, and many other cultures. Records from early Mesopotamia include written formulas using many oils still in use today, including cedar, cypress, and licorice. Around 300 B.C., the Greek philosopher Theophrastus described the medicinal benefits of natural substances in his History of Plants. Throughout the centuries, many philosophers, scientists, and physicians continued collecting, combining, and documenting the use of natural products to treat different illnesses.1

       

      As the science of medicine developed, so did the science of pharmacology. Isolation of the active ingredients found in herbal substances lead to the development of synthetic compounds with similar properties. The first synthetic medication, chloral hydrate, derived from chloroform and discovered in the 1800s by German chemist Justus von Lieberg, is still in use today.2

       

      Fast forward to modern day, and the interest and use of prescription medications, over-the-counter (OTC) products, and dietary supplements are at an all-time high. In 2020, consumers filled 6.3 billion prescriptions in the United States3 (U.S.) and purchased more than 6 billion OTC products.4 The dietary supplement market reached an unprecedented level in 2020 with a global spend of $61.2 billion. Experts predict it will reach $128.64 billion by 2028.5

       

      The COVID-19 pandemic, caused by the SARS-CoV-2 acute respiratory coronavirus, significantly impacted our perception and approach to healthcare.6 More and more people use complementary and alternative approaches to healthcare than ever before.7 For example, sales of elderberry supplements more than doubled and zinc products quadrupled shortly after the pandemic's start.8

       

      Pharmacists, widely recognized as drug information experts, and pharmacy technicians routinely field consumers' questions about dietary supplements. Many pharmacists lack the necessary knowledge or don't know where to look to answer these questions. Pharmacy schools educate future pharmacists on prescription and OTC medications with courses about nutrition and dietary supplementation, if offered, available as electives. This continuing education activity presents information about dietary supplements through a series of seven common pharmacy situations and lets learners in on seven secrets they can apply to their practices.

       

       

       

      Situation: Continuing education is a professional requirement many pharmacists find tedious. Looking through the UCONN online CE library and seeing a new continuing education activity entitled ‘Seven Secrets of Patient Safety with Dietary Supplements,’ a pharmacist remarks to the pharmacy team, "What a waste, no one even takes dietary supplements."

       

      Secret #1: Almost 60% of people in the United States used a dietary supplement in the last 30 days.11,12

       

      Dietary supplements crowd the aisles in drug stores, supermarkets, warehouse clubs, and even corner convenience stores. The sheer number of products is staggering. The Dietary Supplement Database (DSLD) is an online, searchable database developed by the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH). The database contains product labeling information on dietary supplements sold in the United States, including both on and off-market products. DSLD currently lists more than 140,000 labels.9

       

      In the early 1960s, the National Center for Health Statistics began a program named the National Health and Nutrition Examination Survey (NHANES). NHANES is a continuous program focusing on various health and nutritional measurements and assesses adults' and children's health and nutritional status in the U.S.10 Scientific and technical journals publish the study results.

       

      One section of the program assesses dietary supplement use among adults. Results from the 2017-2018 NHANES show that11,12

      • 57.6% of adults 20 years or older used a dietary supplement in the past 30 days
      • Women (63.8%) had a higher utilization than men (50.8%)
      • Use of dietary supplements increased with age, with women 60 years or older reporting the highest usage at 80.2%
      • Use of multiple dietary supplements increased with age
      • Most common dietary supplements used by all age groups include multivitamin-mineral supplements, vitamin D, and omega-3 fatty acids

       

      The Council for Responsible Nutrition (CRN) is a trade association for the dietary supplement and functional food industry. Annually, the CRN performs a survey gathering data on consumer use of dietary supplements. The 2019 survey conducted by the CRN underscored dietary supplement usage with the following results13:

      • 77% of US adults take dietary supplements, including 79% of American women and 74% of males
      • Top reasons for taking supplements included:
        • Energy
        • Immune health
        • Filling nutrient gaps
        • Healthy aging
        • Heart health

       

      The COVID-19 pandemic significantly impacted our perception and approach to healthcare.6 As of August 5, 2022, SARS-CoV-2 has infected more than 580 million people worldwide.14 Interest in boosting our overall immunity and protecting ourselves from viral infections has dramatically increased as a result.7 Many vitamins and minerals play essential roles in proper immune function.7,15 Sales of supplements associated with boosting immunity increased over the last two years, including vitamins C and D, zinc, omega-3, garlic, ginger, and turmeric.16

       

      Table 1. Common Dietary Supplements and Potential Uses7,17,18

       

      Dietary Supplement Potential Use
      Black Cohosh Menopausal symptoms
      Calcium Dyspepsia

      Osteoporosis

      Premenstrual syndrome

      Echinacea Prevention and treatment of the common cold

      Promotion of wound healing

      Elderberry Prevention of upper respiratory tract infections

      Reduction in duration and severity of symptoms of the common cold

      Folic acid Folate deficiency

      Kidney failure

      Neural tube defects

      Ginkgo Anxiety

      Dementia

      Memory improvement

      Premenstrual syndrome

      Ginger Dysmenorrhea

      Nausea and vomiting

      Osteoarthritis

      Ginseng Cognitive function

      Erectile dysfunction

      Iron Anemia

      Restless leg syndrome

      Magnesium Constipation

      Dyspepsia

      Melatonin Sleep disorders
      Multivitamin with minerals General supplementation
      Omega-3 fatty acids

       

       

      Alzheimer’s disease

      Cardiovascular disease

      Dementia

      Depression

      Reduction of triglycerides

      Potassium Hypokalemia

      Hypertension

      Kidney stones

      Probiotics

       

       

      Atopic dermatitis

      Antibiotic-associated diarrhea

      Irritable bowel syndrome

      St. John’s Wort Anti-depressant

      Menopausal symptoms

      Turmeric Allergic rhinitis

      Osteoarthritis

      Pruritis

      Valerian Insomnia
      Vitamin A Aging skin

      Healthy vision

      Vitamin B-12 Vitamin B-12 deficiency
      Vitamin C Anemia

      Antioxidant effects

      Prevention of the common cold

      Vitamin C deficiency

      Vitamin D Osteomalacia

      Osteoporosis

      Vitamin D deficiency

      Vitamin E Alzheimer's disease

      Dysmenorrhea

      Premenstrual syndrome

      Zinc Acne

      Depression

      Diabetes

      Diarrhea

      Treatment of common cold

       

       

      Eating a healthy diet is essential for good health and nutrition. The Dietary Guidelines for Americans advise professionals, including policymakers, health care providers, and nutrition educators, about what to eat to meet the body’s nutritional needs. It emphasizes eating a diet rich in nutrient-dense foods, such as fruits and vegetables, as the best way to meet the body’s nutritional needs. The guideline identifies specific populations in which dietary supplementation may be necessary, such as women who are pregnant or lactating and adults older than 50.19

       

      In addition to these defined special populations, many pharmacy patients may find it necessary to take specific vitamins or minerals due to medication-induced nutrient deficiencies.

       

      Table 2. Examples of Nutrient Depletion Induced by Medications7,17

       

      Nutrient Medication(s) Mechanism
      Vitamin D Anticonvulsants

       

      Increase hepatic metabolism
      Bile acid sequestrants

       

      Decrease absorption
      Orlistat

       

      Decrease absorption
      Magnesium

       

      Estrogens

       

      Decrease serum levels by increasing uptake into tissues
      Loop diuretics

       

      Increase excretion
      Proton pump inhibitors

       

      Decrease absorption
      Vitamin B12

       

       

      Biguanides

       

      Decrease absorption
      Proton pump inhibitors

       

      Decrease absorption
      H-2 blockers

       

      Decrease absorption
      Potassium Loop diuretics

       

      Increase excretion
      Thiazide diuretics

       

      Increase excretion
      Corticosteroids

       

      Increase excretion

       

      The pharmacist's dismissal of dietary supplement education is understandable. No one wants to waste precious time on irrelevant continuing education. However, the facts presented here illustrate the need for pharmacist education on dietary supplements.

      Pause and ponder: A patient presents information about taking lemon and baking soda tea to prevent COVID-19 infection and asks you if it really works. How would you approach this conversation?

       

      Situation: Sunday afternoons sometimes (but not often!) present the opportunity to catch up on administrative activities. While completing an inventory reconciliation of the vitamin section, a technician inquires, "Why does the FDA approve so many different products?" Looking up distractedly from the CII safe count, the pharmacist pauses, then replies in a weary voice, "You know, I’m not sure, probably just to make it more confusing for us."

       

      Secret #2: Regulatory oversight of dietary supplements differs from prescription and OTC medications.

       

      What is a Dietary Supplement?

       

      On the most basic level, a dietary supplement is a substance consumed to add nutrients to a diet or to lower the risk of certain health problems. The use of natural substances has been around for millennia, but it is only within the last five decades that countries worldwide have formalized language and regulations around dietary supplements. Terminology, quality control, and safety assessment differ depending on the country and governing legislative body.20

       

      In 1994, the United States Congress passed the Dietary Supplement Health and Education Act (DSHEA), an amendment to the Food, Drug, and Cosmetic Act. DSHEA defines the term dietary supplement as a product intended for ingestion and containing an ingredient that supplements the diet. Dietary supplement labeling must include the term ‘dietary supplement’ or an equivalent term such as ‘herbal supplement’ or ‘magnesium supplement.’ DSHEA also stipulates that a dietary supplement must be free of contamination, adulteration, and properly labeled.21 We will discuss dietary supplement product integrity and labeling later in this activity.

       

      According to DSHEA, dietary supplements include vitamins, minerals, herbs, other botanicals, amino acids, and live microbials (probiotics). Dietary supplements are available in many different formulations including tablets, capsules, soft gels, gel caps, powders, and liquids.21

       

      DSHEA defined the term ‘new dietary ingredient’ as an ingredient that meets the above criteria and was unavailable in the U.S. before October 15, 1994. If manufacturers want to market a product containing a new dietary ingredient, they must notify the U.S. Food and Drug Administration (FDA) before marketing. The FDA then reviews the product for safety but not effectiveness.21

       

      Regulation of Dietary Supplements

       

      The FDA and the Federal Trade Commission (FTC) share regulation and oversight of dietary supplements. The FDA is responsible for the information provided on dietary supplement product labeling, including the package labeling, product inserts, and information available at the point of sale. The FTC monitors dietary supplement advertising, ensuring advertisements are truthful, substantiated, and not misleading. Both agencies have the authority to address violations and work together to ensure their efforts are consistent with one another.22

       

      The FDA does not have the authority to approve dietary supplement products before manufacturers market, distribute, and sell them to consumers. Manufacturers are responsible for ensuring the products they produce and distribute meet all quality standards defined by federal law. Quality standards include22

      • Ensuring the safety of the dietary ingredients used in the product
      • Following current Good Manufacturing Practices (cGMP)
      • Meeting all product labeling requirements
      • Ensuring substantiation of all claims made about the product
      • Ensuring products are free of adulteration or misbranding

       

      cGMP, defined and regularly updated by the FDA, establish the minimum requirements for manufacturing, packaging, and labeling products to ensure product quality. cGMP includes guidance on obtaining quality ingredients, operating procedures, and quality controls.23 Failure to follow cGMP results in possible product contamination.

       

      While the FDA may not have the authority to approve dietary supplements before the product marketing and distribution, it can monitor products via post-marketing surveillance and auditing. The FDA routinely performs manufacturer inspections, monitors the marketplace, and investigates adverse event reports. Follow-up includes working with the manufacturer to bring the product into compliance, issuing warning letters, and recalling products.21

       

      Reporting Issues with Dietary Supplements

       

      Post-marketing surveillance is essential for documenting and monitoring any issues with dietary supplements. Information about severe reactions and product quality are important issues to report. The FDA Safety Reporting Portal is an online tool used to report safety issues on several categories of products, including pet or livestock foods, tobacco products, animal drugs, and dietary supplements.24

       

      The website address for the portal is https://safetyreporting.hhs.gov. Anyone can use the portal to report issues, including consumers, healthcare professionals, manufacturers, and researchers. Generating a new report starts on the home screen. The reporter chooses to file the report as a guest or by creating an account. Creating an account streamlines data entry and allows the reporting individual to save a draft of the report, follow up on a report, and view previous submissions.24

       

      Generation of an Individual Case Safety Report ID (ICSR) occurs after report submission. The ICSR allows the reporter to identify the report for future reference including submission of a follow-up report with additional information. FDA reviewers assess the seriousness of the reported issue and assign follow-up. Submission of this information allows the FDA to identify potentially dangerous products and potentially remove them from the market.24

       

      Traditionally, insurance companies limit coverage to prescription medications. Recent trends show an expansion of coverage to include some dietary supplements. Insurance coverage of dietary supplements blurs the regulatory differences between prescription medications and dietary supplements. Understanding the differences in oversight is beneficial and allows the pharmacy staff to counsel patients effectively.

      Situation: While running back to the pharmacy after a much-needed bathroom break, a pharmacist stops when approached by a customer asking for advice about an iron supplement. Overhearing the inquiry, another customer comments, "You should buy that online; it’s cheaper, and the quality is just as good." The pharmacist nods assent, turns, and hurries back to the pharmacy amid the erupting sounds of chaos behind the counter.

       

      Secret #3: Product integrity fluctuates between manufacturers and sources of dietary supplements.

       

      Integrity of Dietary Supplements

       

      The lack of government oversight opens the door for substandard products to flood the market. Poor ingredient quality, heavy metal or microbial contamination, adulteration, and mislabeling occur regularly. In the current economy, with rising prices, consumers are turning to less expensive options, and cheaper is not necessarily better, especially with dietary supplements.

       

      In the literature, many studies exist that analyze dietary supplement product integrity. A study published in 2021 tested multiple bottles of 29 herbal supplements for consistency of ingredient activity and the presence of metal and fungal contaminants. The analysis showed inconsistent ingredient activity not only between bottles of the same product manufactured by the same company, but also between bottles manufactured by different companies. Assaying for metal contamination found zinc in 88% of bottles and nickel in 40% of bottles. In 37 of 58 bottles tested, fungal contamination was present, with 21 bottles having multiple strains.25

       

      Another study analyzed 41 dietary supplements for the presence of cadmium, lead, and mercury. Results revealed that 68.3% of samples contained contamination with cadmium and lead, and 29.3% with mercury.26 One research team evaluated 121 dietary supplements along with 49 prescription drugs for levels of toxic element contamination. A small percentage of the dietary supplement products exceeded safety levels for mercury, lead, cadmium, arsenic, or aluminum. None of the prescription products exceeded these safety levels.27

       

      Adulterated products contain substances not listed on the product labeling, substitution of inferior materials for active ingredients, or may contain a lesser amount of ingredients. Weight loss, sports enhancement, and sexual function supplements commonly contain banned substances.28

       

      The FDA created and currently maintains the Health Fraud Product Database to increase awareness. This database contains information about products cited in warning letters, advisory letters, recalls, public notifications, and press announcements for various issues. Issues cited include products claiming to cure, treat, or prevent a disease and products containing undeclared ingredients or a new dietary ingredient.29 The database is available in the consumer section of the FDA website at https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database.

       

      On January 2, 2022, the FDA issued a warning letter to the manufacturers of Nasitrol, a nasal spray based on the ingredient iota carrageenan. A review of the product’s website found claims that the product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Federal regulations define products making these claims as drugs and subject to review by the FDA before approval and subsequent marketing. As discussed earlier, this is in direct violation of federal regulations.30

       

      In another example, on July 15, 2022, the FDA issued a public notice advising consumers to refrain from purchasing Adam’s Secret Extra Strength Amazing Black, a product promoted for sexual enhancement. Laboratory analysis found that the product contained tadalafil, a prescription medication used for erectile dysfunction.31 Due to the potential for severe side effects such as hypotension, tadalafil administration requires medical supervision by a physician.32

       

      A study published in 2018 analyzed FDA warning letters issued from 2007 through 2016, using data from the Health Fraud Product Database. During this time frame, the FDA found 776 adulterated dietary supplements from 146 different companies. A total of 157 products contained more than one unapproved ingredient. Products marketed for sexual enhancement accounted for 45.5% of letters, weight loss 40.9%, and muscle building 11.9%. Unapproved ingredients included sildenafil in sexual enhancement, sibutramine in weight loss, and synthetic steroids or steroid-like ingredients in muscle building supplements.33

       

      One way for consumers to know they are purchasing a valid product is by looking for a certified product. The certification process involves an independent, third-party company testing a company’s products, offering quality assurance for dietary supplements. Parameters tested include34

      • Product contains the ingredients stated on the label
      • Presence of harmful ingredients
      • Presence of contamination
      • Proper dissolution
      • cGMP followed during manufacture

       

      Three independent, private, third-party certifying organizations operate in the United States: the US Pharmacopeial Convention (USP), NSF International, and Consumerlabs.com. All three companies offer product certification programs for a fee. Each company allows products passing certification to display a seal on product labeling. Table 3 summarizes information about each organization.

       

      Table 3. Dietary Supplement Certification Organizations

       

      Certifying Organization US Pharmacopeial Convention NSF International Consumerlab.com
      Website www.usp.org

      www.qualitysupplements.org

       

      www.nsf.org www.consumerlab.com
      Services offered Dietary supplement verification program including GMP facility audits, product QCM process evaluation, and product testing Product and ingredient certification

      GMP Certification

      Certified for Sport

      Product reviews

      Quality Certification Program

      Information available on the website Program information, list of verified products, and educational resources Program information, product search engine, and educational resources Product reviews, health condition information
      GMP = Good Manufacturing Practice

      Source: adapted from reference 33

       

      Online product ordering is a convenient shopping option rapidly gaining popularity in recent years, especially during the pandemic. While tempting to order the least expensive product, investigating the source and quality of dietary supplements available online is essential. Proactive training of the entire pharmacy team aids in providing patients with accurate information.

      Situation: A weary technician finally finishes ringing out the last customer after two hours straight at the register. A sigh of relief quickly turns into a disgruntled groan as another customer approaches. With a bottle labeled ‘Menopausal Support’ in hand, the customer points to the bottle label and asks, "What does ‘proprietary blend’ mean?" The technician glances over her shoulder, sees the pharmacist engaged in an intense phone conversation, and replies to the customer, "The bottle label clearly lists the ingredients."

       

      Secret #4: Federal regulations define required dietary supplement label information. Unfortunately, ambiguity still exists, making it challenging to identify exactly what the product contains.

       

      Federal regulations define the information required on dietary supplement product labeling in detailed, specific terms. Product labeling must include35

      • Product name
      • The term ‘dietary supplement’ or similar term (i.e., herbal supplement)
      • Name and location of the manufacturer, along with a domestic address and phone number for reporting serious adverse events
      • Nutrition labeling in the form of a “Supplement Facts” panel with the following information (see Figure 1):
        • Serving size
        • Number of servings per container
        • Listing of each dietary ingredient in the product
        • Amount of dietary ingredient per serving (Exception: ingredients in a proprietary blend)
        • Amount per serving listed as a quantitative amount by weight, as a percentage of the Daily Value, or as both
      • A list of other ingredients not declared on the Supplement Facts label (usually excipients such as preservatives or dyes)
      • Net quantity of contentsImage of a Supplemental Facts label found on dietary products.

      Figure 1. Supplemental Facts Label (sourced from reference 36)

      One area of ambiguity in dietary supplement product labeling is the listing of a proprietary blend. The term proprietary blend refers to a blend of dietary ingredients unique to a manufacturer and product. Federal labeling regulations allow the listing of proprietary blends on dietary supplement products, however, only the total weight of the blend is required, not the weight of individual ingredients.35 There is no way for the healthcare professional or consumer to know exactly how much of a particular ingredient the proprietary blend contains.

       

      Consumerlabs.com cautions consumers about products containing proprietary blends or formulas. In many instances, the blend's name sounds like a desired, expensive ingredient that is only a small part of the formula. Marketing of products containing proprietary blends may mislead the consumer with claims meant to impress the consumer and drive sales of the product.37

       

      FDA regulations do allow structure/function claims on dietary supplement labeling. Structure/function claims describe how a nutrient or dietary ingredient may affect or act to maintain the structure or function of the body.35 Examples of structure/function claims include35

      • Calcium builds strong bones
      • Antioxidants maintain cell integrity
      • Fiber maintains bowel integrity

       

      If a dietary supplement label contains a structure/function claim it must also contain the following statement: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."35

       

      The example in this situation involved a product marketed for menopausal support. Menopausal symptoms affect more than 1 million women in the US annually and include symptoms such as hot flashes and sleep disturbances.38 A search of the DSLD using the term ‘menopausal support’ and filtering for on-market products containing the ingredient ‘proprietary blend’ returned almost 3,000 products.9 This abundance of products illustrates the ambiguity that exists on dietary supplement labeling.

       

      Pharmacy technicians are often the first line of contact at the pharmacy. Training and development of pharmacy technicians on the facts surrounding dietary supplements empower technicians, allowing them to answer factual questions and provide effective patient education.

       

      Situation: The pharmacy phone constantly rings throughout the day, and today is no exception. The new COVID vaccine is out, and everyone wants to know if the pharmacy has it in stock. Answering yet another call, the technician is surprised when a patient asks to talk to the pharmacist, complaining about dizziness. The pharmacist checks the patient’s profile, finding no underlying causative medication. Further questioning the patient, the pharmacist uncovers the recent addition of melatonin at night for sleep.

       

      Secret #5: Like prescription medications, dietary supplements have pharmacologic and physiologic effects on the body, potentially resulting in health risks and side effects.

       

      Consumers perceive dietary supplements as safe due to their source from natural substances. While generally well tolerated, dietary supplements affect the body like prescription medications, capable of producing an undesired effect. Lack of regulatory oversight allows products to reach consumers without adequate safety evaluation.

       

      Information describing adverse effects of dietary supplements is anecdotal, derived from case reports and reports submitted through the FDA Safety Reporting Portal. Most dietary supplements have not been studied in pregnant or lactating women or children.

       

      A study published in 2015 evaluated ten years of emergency room data to assess the number of annual visits resulting from dietary supplement adverse events. The authors calculated an average of more than 23,000 emergency room visits stemmed from the consumption of dietary supplements, resulting in more than 2,000 hospitalizations annually.39

       

      Events in older adults accounted for the highest percentage of visits, with 40% of visits due to difficulty swallowing. Incidence in young adults aged 20 to 34 was significant at 28% and primarily involved weight loss and energy products. Side effects reported include heart palpitations, chest pain, and tachycardia.39

       

      Unsupervised child ingestions accounted for 21% of visits. Unlike prescription medications, regulations do not require child-resistant packaging for dietary supplements, except for iron-containing products.39 The authors note the numbers evaluated in the study are likely underreported as patients do not always include dietary supplements with the current medication list.39

       

      Table 4. Adverse Effects of Common Dietary Supplements7,17

       

      Supplement Adverse Effects
      Black Cohosh

       

      Breast tenderness, diarrhea, gastrointestinal upset, nausea/vomiting
      Calcium

       

      Burping, constipation, gastrointestinal upset
      Echinacea

       

      Diarrhea, constipation, gastrointestinal upset/pain, heartburn, nausea/vomiting, skin rashes
      Ginseng Gastrointestinal side effects, headache, sleep difficulty
      Ginger

       

      Burping, diarrhea, heartburn
      Iron

       

      Abdominal pain, constipation, diarrhea, nausea/vomiting
      Magnesium

       

      Diarrhea, gastrointestinal irritation, nausea/vomiting
      Melatonin

       

      Dizziness, drowsiness, headache
      Omega-3 fatty acids Bad breath, headache, heartburn, nausea, diarrhea, unpleasant taste
      Potassium

       

      Abdominal pain, burping, diarrhea, nausea/vomiting
      St. John’s Wort

       

      Diarrhea, dizziness, dry mouth, fatigue, headache, insomnia
      Turmeric

       

      Constipation, dyspepsia, gastrointestinal reflux, nausea/vomiting
      Vitamin C

       

      Abdominal cramping, heartburn, kidney stones (if history of kidney stones)
      Zinc

       

      Abdominal cramping, diarrhea, metallic taste, nausea/vomiting

       

       

      Patients often fail to report usage of dietary supplements and most pharmacy software lacks the ability to note dietary supplement usage in the patient profile. In this situation, the pharmacist took the extra time to further question the patient about dietary supplement usage and successfully identified the causative agent.

       

      Pause and Ponder: In what ways could you incorporate activities into the daily workflow to increase awareness of patients’ use of dietary supplements?

       

      Situation: Today, the workload in the pharmacy is lighter than usual. With a grateful sigh, the pharmacist sinks onto a stool reaching for a quick snack. Then the phone rings… The caller is a triage nurse from the local hospital to verify a patient’s medication profile. Pulling up the profile, the pharmacist verifies the list of medications, including digoxin. The triage nurse confirms atrial fibrillation as the cause for admission, adding that the patient recently started taking St. John’s Wort for depression.

       

      Secret #6: Some dietary supplements affect the CYP450 liver enzymes, potentially altering the pharmacokinetics of medications, leading to treatment failure and/or toxicity.

       

      Dietary supplement-drug interactions

       

      Drug-drug interactions result in altered absorption, metabolism, or excretion. Drug-dietary supplement interactions occur through the same pathways as those used by FDA-approved drugs. The cytochrome P450 (CYP P450) enzymes in the liver are responsible for the metabolism of most medications.41,42 The ability of a drug to either induce or inhibit these enzymes is a significant factor in drug-drug interactions. The natural ingredients found in dietary supplements are capable of inhibition or induction, also having the potential to interact with medications.

       

      St. John’s Wort, an herbal commonly taken for the relief of mild to moderate depression, induces the activity of CYP3A4.43,44 This induction increases the clearance of medications metabolized by CYP3A4. Examples of medications cleared by CYP3A4 include alprazolam, atorvastatin, cyclosporine, oral contraceptives, oxycodone, and warfarin.43,44 Patients need counseling about potential drug interactions with St. John’s Wort.

       

      Limited clinical studies evaluating the impact of drug-dietary supplement interactions exist. Many interactions are theoretical, based on limited clinical evidence, animal research, and case reports.

       

      Table 5. Examples of Potential Drug-Dietary Supplement Interactions7,17

       

      Dietary Supplement Medication Interaction
      Calcium

       

       

      Quinolone and tetracycline antibiotics Decreased antibiotic efficacy

      Take antibiotic 2 hours before or 4-6 hours after calcium

      Dolutegravir

      Elvitegravir

      Reduced serum levels

      Take medication 2 hours before or 2 hours after calcium

      Ginseng Diabetes medications Increase risk of hypoglycemia
      Immunosuppressants Decreased effectiveness of immunosuppressant
      Ginkgo

       

      Anticoagulants Increased risk of bleeding
      Iron

       

      Quinolone and tetracycline antibiotics Decreased levels of antibiotics due to decreased absorption

      Take antibiotics 2 hours before or 4-6 hours after iron

      Magnesium

       

      Bisphosphonates Decreased absorption

       

      Levodopa/carbidopa Decreased bioavailability of levodopa/carbidopa
      Niacin

       

       

       

      Statins Increased risk of myopathy or rhabdomyolysis
      Thyroid hormones Antagonize the effects of thyroid hormone replacement
      Antihypertensive medications Increased risk of hypotension due to niacin’s vasodilating effects
      St. John’s Wort Alprazolam Decreased effects of alprazolam
      Oral Contraceptives Decreased efficacy

      Counsel patients to use other forms of contraception

      Digoxin Decreased levels of digoxin
      Omeprazole Decreased effects of omeprazole
      Valerian CNS depressant drugs Additive sedative effects
      Vitamin B6

       

      Phenytoin Decrease levels and clinical effects of phenytoin
      Vitamin D

       

      Atorvastatin Decreased absorption of atorvastatin
      Vitamin E

       

      Anticoagulants Increased risk of bleeding
      Zinc

       

      Quinolone antibiotics Decreased levels and effects of antibiotics

      Take antibiotic 2 hours prior or 4-6 hours after zinc

       

      Pharmacy training emphasizes the importance of drug-drug interactions. It is important to remember that any substance introduced to the body, including food, beverages, and dietary supplements, has the potential to interact with medications.

      Situation: It is another busy day in the pharmacy; prescriptions cover the bench, the phone rings constantly, and a pickup queue extends around the corner. A technician nervously approaches the pharmacist about a patient at the counter with a question regarding a supplement. The pharmacist throws down the spatula, muttering angrily about lacking the knowledge and training to answer the question properly. Sighing, he says, "I’ll just Google it."

       

      Secret #7: Many websites provide clinically backed information on dietary supplements (and Google is not one of them!).

       

      The vast amount of health information available via the Internet with just a few clicks of the keyboard is both a blessing and a curse. Google is now a verb, and a simple search returns millions of results in seconds. While this may seem like a blessing, the curse lies in the searcher's inability to recognize valid, accurate sources of information. In many searches, ads appear as search results adding to the confusion.

       

      In addition to the Internet, consumers turn to social media for health information. Social media use increased from 27% in 2009 to 86% in 2019.45 Information posted on social media provides communication about healthcare issues, potentially resulting in improved health care.45 Unfortunately, inaccurate information abounds on the Internet and social media platforms, leading to consumer misinformation.47-49

       

      The FDA recently launched a new dietary supplement education initiative geared towards consumers, healthcare professionals, and teachers. The program, Supplement Your Knowledge, presents information about dietary supplements through a series of three videos. Educational materials, including fact sheets and infographics, are available in English and Spanish.50

       

      Many government agencies provide free access to information about dietary supplements and their side effects, toxicity, and drug interactions. There are also several paid subscription resources available. Table 6 lists many of the available information options.

       

      Table 6. Sources of Information about Dietary Supplements

       

      Resource Website Information
      Dietary Supplement Education Program https://www.fda.gov/food/healthcare-professionals/dietary-supplement-continuing-medical-education-program

       

      • Continuing medical education program
      • Collaboration between FDA and AMA
      • Series of 3 videos about dietary supplements
      • Also contains links to educational materials and other websites with information about dietary supplements
      Dietary Supplement Label Database https://dsld.od.nih.gov

       

      • Current and historical label information on dietary supplement products marketed in the United States
      • Useful to determine the contents of dietary supplement products
      Food and Drug Administration https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements

       

      • Information for consumers on using dietary supplements
      • Links to educational resources and materials, consumer updates, alerts, recalls and other information
      Google Scholar

       

      https://scholar.google.com/

       

      • Source of information from many avenues including journals, books, and conference proceedings
      Lexi-Comp

      Natural Products Database

      Available via mobile app
      • Requires a paid subscription
      • Alphabetical, searchable natural product database
      Memorial Sloane Kettering Cancer Center https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs

       

      • Information on herbs, botanicals, and other products for both consumers and healthcare professionals
      • Dietary supplement monographs
      • IOS app: About Herbs
      • Part of an online integrative medicine resource center
      National Cancer Institute Office of Cancer Complementary and Alternative Medicine https://cam.cancer.gov

       

      • Information for consumers and healthcare professionals about CAM as it relates to cancer therapy
      • Information on current NCI CAM research
      National Center for Complementary and Integrative Health https://www.nccih.nih.gov

       

      • Information for both consumers and healthcare professionals about complementary health products and practices
      National Library of Medicine - Medline Plus https://medlineplus.gov/druginfo/herb_All.html

       

      • Online health information about drugs, herbs, and supplements for consumers
      • Information sourced from the National Center for Complementary and Integrative Health and Natural Medicines Comprehensive Database
      Natural Medicines Comprehensive Database https://naturalmedicines.therapeuticresearch.com

       

      • Requires a paid subscription
      • Professional monographs including information about effectiveness, safety, adverse effects, and interactions
      • Information on specific commercial products
      • Interaction checker
      • Patient handouts in English, Spanish and French
      Office of Dietary Supplements https://ods.od.nih.gov
      • Information for both consumers and healthcare professionals
      • General supplement information
      • Information on supplements for specific purposes
      • Fact sheets on dietary supplements and their ingredients
      PubMed https://pubmed.ncbi.nlm.nih.gov

       

      • Search engine for the National Library of Medicine
      • Source of information from journals
      United States Department of Agriculture https://www.nutrition.gov/topics/dietary-supplements

       

      • Links to general information and resources on dietary supplements

       

       

      Performing an Internet search via Google may seem like the quickest and easiest way to find the answer to an inquiry. Engaging with the patient, gaining additional information, and knowing where to look ultimately saves time. It is not necessary for one to be an expert in all dietary supplements, just to self-educate one supplement at a time.

       

      Pause and Ponder: A patient shares the unfortunate news about a recent cancer diagnosis. He asks you about the use of herbs in the treatment of cancer. What advice would you give? 

      Conclusion

      You may have noticed a recurring theme throughout this activity. Education. Dietary supplement education is essential to patient safety given the current usage patterns and accessibility of the retail pharmacy team. Education needs to include the entire pharmacy team. Technicians are often the first point of contact at the pharmacy, commonly fielding patient questions. Knowing when to answer questions and when to involve the pharmacist is a necessary skill. Understanding the differences in oversight, the physiological effects of dietary supplement consumption, and the potential for drug interactions allows effective management and counseling of patients. It is important for healthcare providers to solicit information regarding patient consumption of dietary supplements.

       

       

      Sidebar: Tips for Counseling Patients about Dietary Supplements

       

      Carefully inspect the product to ensure intact product labeling

      Ensure the safety seal is intact

      Check for an expiration date or best used by date

      Check for customer service or return information before ordering

      Buy direct from a reputable company; many reputable companies sell through Amazon, avoid 3rd party resellers

      Check for the presence of a third-party certification seal

      Before purchase, check the company’s website for information on quality standards

      Pay attention to the appearance and smell of the product upon opening

      Child-resistant packaging is not a requirement for dietary supplements; advise on proper storage of product

      Reinforce the importance of including dietary supplements on a current medication list

       

       

       

       

      Pharmacist Post Test (for viewing only)

      Seven Secrets for Patient Safety with Dietary Supplements

      Pharmacist post-test

      After completing this continuing education activity, pharmacists will be able to:

      1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
      2. Identify commonly used dietary supplements, their regulation, and the value of certification (K, or A?)
      3. Recognize potential medication-dietary supplement interactions (K)
      4. Demonstrate the ability to locate different sources of information about dietary supplements (A)

      1. According to The National Health and Nutrition Examination Survey more than what percentage of adults have used a dietary supplement in the last 30 days?

      A. 45%
      B. 50%
      C. 55%

      2. Which of the following is a commonly used dietary supplement?

      A. Boswellia
      B. Turmeric
      C. Quercetin

      3. Which government agencies regulate dietary supplements?

      A. USDA, FDA
      B. FTC, DEA
      C. FTC, FDA

      4. Patient MW fills a new prescription for bumetanide. Which potential nutrient depletion may occur?

      A. Magnesium
      B. Vitamin D
      C. Vitamin B12

      5. While completing an inventory reconciliation of the vitamin section, a technician inquires, ‘Why does the FDA approve so many different products?’ Which of the following is the most appropriate answer?

      A. ‘The FDA does not have the authority to approve dietary supplements, the FTC approves dietary supplements, including vitamins.’
      B. ‘The FDA does not have the authority to approve dietary supplements before they are marketed, allowing manufacturers to flood the market with products.’
      C. ‘You know, I’m not sure, probably just to make it more confusing for us.’

      6. Which of the following companies offer independent third-party dietary supplement certification services?

      A. Consumer Reports
      B. NSF International
      C. Certified Naturally Grown

      7. Patient ED is a 58-year-old male new to your pharmacy. He provides the pharmacy team with a list of his current medications including:
      • Warfarin 3 mg PO QD
      • Atorvastatin 10 mg PO QD
      • Donepezil 10 mg PO QHS
      • Metformin 1,000 mg PO BID
      Use of which of the following supplements would be cause for concern in this patient?

      A. Ginkgo
      B. Omega-3 fatty acids
      C. Niacin

      8. A patient calls with questions about a supplement recommended by a friend. The name of the supplement is Mind and Memory Essentials, and the patient does not know the product ingredients. Where would you go to find this information?

      A. Dietary Supplement Label Database
      B. Office of Dietary Supplements
      C. United States Department of Agriculture

      9. A patient asks you about the potential side effects of taking turmeric. Where would you go to find this information?

      A. Google
      B. PubMed
      C. Office of Dietary Supplements

      10. You are verifying a new birth control prescription for a patient, recalling that the patient strongly believes in alternative medicine and dietary supplementation. Thankfully her profile contains a list of dietary supplements. You see St. John’s Wort listed and suspect a drug-supplement interaction. Where would you go to find more information?

      A. Natural Medicines Database
      B. Google Scholar
      C. National Library of Medicine

      11. One of your regular patients stops by the counter to ask your opinion on a dietary supplement product purchased on the Internet. What should you assess when looking over the product?

      A. Product labeling, color of bottle, structure/function disclaimer, certification
      B. Certification, expiration date, product labeling, intact seal
      C. Expiration date, product price, certification, product labeling

      12. Pharmacy patient ML approaches the pharmacy counter to purchase several bottles of oral glucose tablets. When questioned, the patient reveals the recent occurrence of several hypoglycemic episodes. The patient confirms compliance with taking their prescription for metformin 1 gm PO BID. ML reports no changes in other prescriptions or dietary habits but does state they started taking a dietary supplement a few days ago but cannot recall the name. Which product would you suspect based on the information provided?

      A. Vitamin E
      B. Valerian
      C. Ginseng

      Pharmacy Technician Post Test (for viewing only)

      Pharmacy Technician

      After completing this continuing education activity, pharmacy technicians will be able to:

      1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
      2. Identify commonly used dietary supplements (A)
      3. Define dietary supplement oversight and different levels of quality (K)
      4. Recognize the need for pharmacist counseling when a patient is taking a dietary supplement (K)

      1. Why is it important to ask about a patient’s usage of dietary supplements?

      A. It is not important to ask about dietary supplement usage.
      B. To identify which dietary supplements the pharmacy should feature on the front counter.
      C. Dietary supplements potentially interact with prescription medications.

      2. Which of the following is a commonly used dietary supplement?

      A. Boswellia
      B. Turmeric
      C. Quercetin

      3. Which government agencies regulate dietary supplements?

      A. USDA, FDA
      B. FTC, DEA
      C. FTC, FDA

      4. A patient approaches the counter with 2 different magnesium products and asks your opinion on which to purchase. Which of the following is an appropriate answer?

      A. Let’s look at these a little closer.
      B. Neither, it’s better to buy supplements online.
      C. The one that’s on sale.

      5. Reasons for dietary supplementation include which of the following?

      A. To supplement a poor diet.
      B. Promotion of optimal immune health
      C. No one needs to take dietary supplements.

      6. Which of the following companies offer independent third-party dietary supplement certification services?

      A. Consumer Reports
      B. NSF International
      C. Certified Naturally Grown

      7. You are entering a new patient into the pharmacy system. In addition to asking about allergies, demographics, and current medications, what else should you ask?

      A. How many hours of sleep do you average a night?
      B. Do you take any over-the-counter medications or dietary supplements?
      C. How many children do you have and how old are they?

      8. You are finally heading out for a lunch break and walk past a pharmacy patient in the aisle looking at 2 different brands of St. John’s Wort. What should you do?

      A. Keep going, you already punched out and only have 30 min to eat your lunch.
      B. Stop and offer to accompany them to the pharmacy to talk to the pharmacist.
      C. Stop and help them make a choice between the products.

      9. A patient picks up a medication and purchases a bottle of magnesium at the same time. What should you do?

      A. Advise the patient that there may be an interaction between the prescription and the magnesium.
      B. Ring out the patient as usual.
      C. Touch base with the pharmacist to make sure there are no potential interactions between the products.

      10. Where should adverse reactions or issues with dietary supplements be reported?

      A. FDA Safety Reporting Portal
      B. Federal Trade Commission
      C. Office of Dietary Supplements

      References

      Full List of References

      References

        1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-3695. doi:10.1016/j.bbagen.2013.02.008

        2. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3(6):337-344. doi:10.1002/dta.301

        3. Aitken M, Kleinrock M. The Use of Medicines in the U.S. Spending and Usage Trends and Outlook to 2025. IQVIA Institute for Human Data Science. May 2021. Accessed August 5, 2022. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us/iqi-the-use-of-medicines-in-the-us-05-21-forweb.pdf

        4. OTC Sales Statistics. Consumer Healthcare Products Association. Accessed June 22, 2022. https://www.chpa.org/about-consumer-healthcare/research-data/otc-sales-statistics

        5. Dietary Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets, Capsules, Liquids, and Powders), and Regional Forecasts, 2021-2028. Fortune Business Insights. Accessed June 22, 2022. https://www.fortunebusinessinsights.com/dietary-supplements-market-102082

        6. Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343. Published 2021 Mar 16. doi:10.1136/bmjopen-2020-045343

        7. Dietary Supplements in the Time of COVID-19. Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements. Accessed July 20, 2022. https://ods.od.nih.gov/factsheets/COVID19-HealthProfessional/.

        8. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020;54(8):820-826. doi:10.1177/1060028020928052

        9. US Department of Health and Human Services, National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label Database (DSLD). Accessed August 5, 2022. https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx

        10. About the National Health and Nutrition Examination Survey. National Center for Health Statistics. Accessed July 20, 2022. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm

        11. Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017–2018. NCHS Data Brief, no 399. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://doi.org/10.15620/cdc:101131external icon

        12. Gahche JJ, Bailey RL, Potischman N, et al. Federal Monitoring of Dietary Supplement Use in the Resident, Civilian, Noninstitutionalized US Population, National Health and Nutrition Examination Survey. J Nutr. 2018;148(Suppl 2):1436S-1444S. doi:10.1093/jn/nxy093

        13. 2019 CRN Consumer Survey on Dietary Supplements. Council for Responsible Nutrition. https://www.crnusa.org/2019survey. Published September 30, 2019. Accessed June 1, 2022.

        14. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed August 5, 2022.

        15. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. 2020;12(4):1181. Published 2020 Apr 23. doi:10.3390/nu12041181

        16. Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. Nutrients. 2020;13(1):54. Published 2020 Dec 27. doi:10.3390/nu13010054

        17. Natural Medicines. Therapeutic Research Center. Accessed August 2, 2022. https://naturalmedicines.therapeuticresearch.com.

        18. Office of Dietary Supplements Dietary Supplement Fact Sheets. Accessed August 2, 2022. https://ods.od.nih.gov/factsheets/list-all/

        19. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at DietaryGuidelines.gov. https://www.dietaryguidelines.gov/sites/default/files/2021-03/Dietary_Guidelines_for_Americans-2020-2025.pdf

        20. Thakkar S, Anklam E, Xu A, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 2020;114:104647. doi:10.1016/j.yrtph.2020.104647
        21. FDA 101: Dietary supplements. United States Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.
        22. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements.

        23. Facts About the Current Good Manufacturing Practices (cGMPs). U.S. Food and Drug Administration. Accessed July 22, 2022.
        https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

        24. Safety Reporting Portal. Food and Drug Administration. Accessed August 10, 2022. https://www.safetyreporting.hhs.gov/SRP2/en/Home.aspx?sid=da6dc761-7962-4743-82cd-2e62985492d0

        25. Veatch-Blohm ME, Chicas I, Margolis K, Vanderminden R, Gochie M, Lila K. Screening for consistency and contamination within and between bottles of 29 herbal supplements. PLoS One. 2021;16(11):e0260463. Published 2021 Nov 23. doi:10.1371/journal.pone.0260463

        26. Ćwieląg-Drabek M, Piekut A, Szymala I, et al. Health risks from consumption of medicinal plant dietary supplements. Food Sci Nutr. 2020;8(7):3535-3544. Published 2020 May 19. doi:10.1002/fsn3.1636

        27. Genuis SJ, Schwalfenberg G, Siy AK, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One. 2012;7(11):e49676. doi:10.1371/journal.pone.0049676

        28. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

        29. Health Fraud Product Database. United States Food and Drug Administration. Accessed August 10, 2022. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database

        30. Warning Letter: Amcyte Pharma, Inc. United States Food and Drug Administration. January 03, 2022. Accessed August 12, 2022. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amcyte-pharma-inc-623474-01032022

        31. Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient. United States Food and Drug Administration. July 15, 2022. Accessed August 12, 2022. https://www.fda.gov/drugs/medication-health-fraud/public-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient

        32. Coward, RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4(6):1315-1329. Accessed October 3, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/pdf/TCRM-4-1315.pdf

        33. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

        34. Akabas SR, Vannice G, Atwater JB, Cooperman T, Cotter R, Thomas L. Quality Certification Programs for Dietary Supplements. J Acad Nutr Diet. 2016;116(9):1370-1379. doi:10.1016/j.jand.2015.11.003

        35. Dietary Supplement Labeling Guide, U.S. Food and Drug Administration. https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide Accessed July 15, 2022.

        36. Frequently Asked Questions for Industry on Nutrition Facts Labeling Requirements. United States Food and Drug Administration. Accessed August 12, 2022. https://www.fda.gov/media/99158/download

        37. Cooperman, T. 6 Red Flags to Watch Out For When Buying Vitamins & Supplements. October 9, 2021. Accessed August 12, 2022. https://www.consumerlab.com/answers/what-to-watch-out-for-when-buying-vitamins-and-supplements/vitamin-and-supplement-red-flags

        38. Research explores the impact of menopause on women’s health and aging. National Institute of Aging. May 6, 2022. Accessed September 6, 2022. https://www.nia.nih.gov/news/research-explores-impact-menopause-womens-health-and-aging

        39. Geller AI, Shehab N, Weidle NJ, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med. 2015;373(16):1531-1540. doi:10.1056/NEJMsa1504267

        40. Code of Federal Regulations. Title 16, Chapter II, Subchapter E, Part 1700. Amended September 6, 2022. Accessed September 6, 2022. https://www.ecfr.gov/current/title-16/chapter-II/subchapter-E/part-1700/section-1700.14

        41. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093-1108. doi:10.1007/s00216-008-2291-6

        42. Matura JM, Shea LA, Bankes VA. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations [published online ahead of print, 2021 Nov 4]. Ir J Med Sci. 2021;10.1007/s11845-021-02828-4. doi:10.1007/s11845-021-02828-4

        43. Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-138. doi:10.1111/jphp.12858

        44. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18(2):262-276. doi:10.1177/0269881104042632

        45. Chen J, Wang Y. Social Media Use for Health Purposes: Systematic Review. J Med Internet Res. 2021;23(5):e17917. Published 2021 May 12. doi:10.2196/17917

        46. Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15(4):e85. Published 2013 Apr 23. doi:10.2196/jmir.1933

        47. Swire-Thompson B, Lazer D. Public Health and Online Misinformation: Challenges and Recommendations. Annu Rev Public Health. 2020;41:433-451. doi:10.1146/annurev-publhealth-040119-094127

        48. Chou WS, Oh A, Klein WMP. Addressing Health-Related Misinformation on Social Media. JAMA. 2018;320(23):2417-2418. doi:10.1001/jama.2018.16865

        49. Suarez-Lledo V, Alvarez-Galvez J. Prevalence of Health Misinformation on Social Media: Systematic Review. J Med Internet Res. 2021;23(1):e17187. Published 2021 Jan 20. doi:10.2196/17187

        50. Supplement Your Knowledge. Dietary Supplement Education Initiative. United States Food and Drug Administration. May 25, 2022. Accessed July 20, 2022. Reference the Supplement your knowledge program

        Henry A. Palmer CE Finale LIVE Event Friday, Dec 13, 2024

        Photograph of Henry A. Palmer

        The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. Pharmacists may enroll in one or more [up to 8] hours of continuing education.

        The University of Connecticut

        School of Pharmacy

        Presents the

        Henry A. Palmer C.E. FINALE 2024

        Aged to Perfection: Pharmacist Strategies for Elder Care Excellence

        A LIVE (both virtual and in-person) application and knowledge-based continuing education activity for practicing pharmacists in all settings

         

        Friday, December 13, 2024

        7:30 AM 5:00 PM Eastern Time
        Sheraton Hartford South,
        Rocky Hill, CT

        For a full course description see the Henry A. Palmer CE Finale Brochure 2024

        REGISTRATION

        Handouts for CE Finale will be available the first week of December

        HANDOUTS FOR CE FINALE (these will be uploaded as available)

        LAW: Medical-Legal Considerations of Aging Patients for Pharmacists-1 slide per page and clickable links

        Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World-6 per page
        Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World
        -2 per page

        Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults -6 per page
        Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults
        -2 per page

        Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults-6 per page
        Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults
        2 per page

        Opioids: Impact of Palliative Care on Total Pain in the Older Adult-6 per page
        Opioids: Impact of Palliative Care on Total Pain in the Older Adult
        2 per page

        Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing-6 per page
        Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
        -2 per page

        Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia6 per page
        Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia
        2 per page

        LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation-6 per page
        LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
        -2 per page

         

        CE FINALE SCHEDULE/TOPICS/LEARNING OBJECTIVES

        7:30-8:00 a.m. – Registration and Check-In/Sign-In

        8:00-8:05 a.m. Opening Remarks- Philip Hritcko, Dean, School of Pharmacy

        8:05-8:10 a.m.Operational Instructions-Jeannette Y. Wick, Dir. OPPD

         

        8:10-9:10 a.m. – LAW: Medical-Legal Considerations of Aging Patients for Pharmacists
        Jennifer A. Osowiecki, RPh, JD, Cox & Osowiecki, LLC, Hartford, CT

        At the conclusion of this presentation, pharmacists will be able to:
        1. List at least three common medical-legal concerns associated with aging.

        2. Identify what constitutes elderly abuse or neglect and describe whether the pharmacist has a reporting obligation.

        3. Discuss the likelihood of polypharmacy and measures that pharmacists can employ to facilitate better medication management and compliance for elderly patients and their caregivers.

        0009-0000-24-042-L03-P     (0.1 CEU or 1 contact hour) (Application-based)

        9:15-10:15 a.m. Law: Seniors Self-Diagnosing and Treating: A Brave (and scary) New World

        Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT   

        At the conclusion of this presentation, pharmacists will be able to:
        1. Describe the reasons seniors are increasingly diagnosing and treating themselves with therapies
        2. Describe the legal and regulatory pathways that provide seniors access to therapies outside the drug supply chain
        3. Describe the ways that pharmacists can recommend dietary supplements that are free of adulterants and contaminants
        4. Describe the risks associated with self-treatment with dietary supplements, “peptides”, and counterfeit drugs

        0009-0000-24-044-L03-P (0.1 CEU or 1 contact hour) (Knowledge-based)

        10:20-11:20 a.m. – Balancing Safety and Efficacy: Addressing Medication Dilemmas in Older Adults

        Christina Polomoff, PharmD, BCACP, BCGP, FASCP, Population Health Clinical Pharmacist, Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT

        At the conclusion of this presentation, pharmacists will be able to:
        1. Analyze pharmacokinetic and pharmacodynamic changes associated with aging
        2. Identify opportunities for deprescribing and medication management
        3. Use evidence-based tools and strategies to optimize medication regimens, applying deprescribing frameworks and decision aids in real-world geriatric care

        0009-0000-24-043-L01-P (0.1 CEU or 1 contact hour) (Application-based)

        11:25-12:25 p.m.  – Immunization: Our Best Shot – Tips and Tools to Vaccinate Older Adults

        At the conclusion of this presentation, pharmacists will be able to
        1.      RECOGNIZE appropriate vaccine recommendations for the older adult population

        2.      IDENTIFY potential barriers to vaccinations

        3.      ANALYZE current methods used to improve vaccination rates

        4.      DISCUSS ways to improve vaccine compliance in your patient population

        0009-0000-24-047-L06-P (0.1 CEU or 1 contact hour) (Application-based)

         

        12:25-12:45 p.m. – BREAK-light snacks will be served.

        12:45-1:45 p.m. – Opioids: Impact of Palliative Care on Total Pain in the Older Adult

        Megan Mitchell, PharmD, MS, Pharmacy Clinical Coordinator Pain Management and Palliative Care, University of Connecticut Healthcare, Farmington, CT         

        At the conclusion of this presentation, pharmacists will be able to:
        1. Describe Palliative Care and its importance in the healthcare system today
        2. Define the concept of “total pain” and the importance of whole person care in pain and symptom management
        3. Recognize the physiologic changes that occur with aging and how those impact pain and symptom management
        4. Determine the role of the pharmacist in total pain management in the older adult

        0009-0000-24-046-L08-P (0.1 CEU or 1 contact hour) (Application-based)

        1:50-2:50 p.m.  –Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
        Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH

        At the conclusion of this presentation, pharmacists will be able to:
        1. Review the role of the Beers Criteria in reducing potentially inappropriate medication (PIM) use and enhancing patient safety in older adults
        2. Identify recent updates to the Beers Criteria and their implications for medication management in geriatric care
        3. Apply the updated Beers Criteria to real-world scenarios, optimizing medication selection and minimizing risks in older adult

        0009-0000-24-045-L05-P  (0.1 CEU or 1 contact hour (application-based)

        2:55-3:55 p.m.  – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

        Kristin Waters, PharmD, BCPS, BCPP, Assistant Clinical Professor, UConn School of Pharmacy, Storrs, CT

        At the conclusion of this presentation, pharmacists will be able to:
        1. Identify clinical characteristics of the behavioral symptoms of dementia (BSD) including agitation, psychosis, and sleep disturbances
        2. Discuss medications currently used in the management of BSD along with emerging pharmacologic therapy options
        3. Determine the most appropriate pharmacologic treatment option for a patient with behavioral symptoms of dementia based on patient-specific factors

        0009-0000-24-048-L01-P  (0.1 CEU or 1 contact hour) (Application-based)

        4:00-5:00 p.m. –LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
        Jeannette Y. Wick, RPh, MBA, Director Office of Professional Pharmacy Development, UConn School of Pharmacy, Storrs, CT

        At the conclusion of this presentation, pharmacists will be able to:
        1. Explain common terminology associated with commercials targeting older Americans
        2. Describe legal processes associated with lawsuits generated against companies that make products alleged to cause harm
        3. Discuss generalities in potential lawsuits associated with media promotion campaigns
        4. Identify areas where no information is available to provide good, valid answers for patients who ask questions

        0009-0000-24-049-L03-P (0.1 CEU or 1 contact hour) (Application-based)

         

        CE FINALE ENCORE WEBINARS AVAILABLE

        If you find you cannot make it to our LIVE EVENT on Friday, December 13th, you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates:

        • Monday, December 16, 12:00 (Noon) – 1:00 pm – Seniors Self-Diagnosing and Treating: A Brave (and scary) New World
        • Monday, December 16, 7:00 pm – 8:00 pm – Patient Safety: Cheers to the Beers: Unpacking the Latest Updates for Safer Prescribing
        • Monday, December 16, 8:10 pm – 9:10 pm –  Immunization:  Our Best Shot – Tips and Tools to Vaccinate Older Adults
        • Tuesday, December 17, 12:00 (Noon) – 1:00 pm – Opioids: Impact of Palliative Care on Total Pain in the Older Adult
        • Tuesday, December 17, 7:00 pm-8:00 pm – LAW: Call 1-800-Get-Cash Fast: Drug-Related Advertisements about Litigation
        • Wednesday, December 18, 12:00 pm-1:00 pm – Beyond Memory Loss: Mastering the Management of Behavioral Symptoms in Dementia

        Registration Information

        Online: https://ce.pharmacy.uconn.edu/henry-a-palmer-ce-finale/

        A continuous class schedule format will be used.  This format does not include breaks but does include a 20 minute lunch period.

        Refunds and Cancellations:  The registration fee, less a $75 processing fee, is refundable for those who cancel their registration three (3) days prior to the program (by December 10) After that time, no refund is available.

        Location: The Henry A. Palmer C.E. Finale will be held both virtually or in-person. You must sign in to the Webex link at the designated time using the link in your confirmation email if you decide to participate virtually.

        Continuing Education Units

          Logo for the Accreditation Council for Pharmacy Education

          The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations.  Pharmacists can earn up to 8 contact hours (0.80 CEU) three of which are Law credits, and one is an Immunization credit, one is a Patient Safety credit and one is an Opioid credit.

          Please Note:  Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (January 27, 2025).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with joanne.nault@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to assure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

          Activity Support:  There is no funding for this program.

           

           

          Patient Safety: Pharmacy Metrics-Recorded Webinar

          About this Course

          This course is a recorded (home study version) of the Pharmacy Metrics Webinar

           

          Learning Objectives

          Upon completion of this application based CE Activity, a pharmacy technician will be able to:

          • Describe the importance of pharmacy metrics for efficient operation.
          • Define pharmacy metrics in various settings.
          • Describe how team members can effectively contribute to the workplace

          Release and Expiration Dates

          Released:  September 15, 2023
          Expires:  September 15, 2026

          Course Fee

          $4  Pharmacy Technician

          ACPE UAN

          0009-0000-23-026-H05-T

          Session Code

          20YC63-BCX86

          Accreditation Hours

          1.0 hours of CE

          Additional Information

           

          How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

          Accreditation Statement

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

          Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-026-H05-T, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

          Grant Funding

          There is no grant funding for this activity.

          Faculty

          Sara Miller, PharmD
          CVS Pharmacist
          Foxboro, MA

          Kyra Durfee, PharmD Candidate 2022
          UConn School of Pharmacy
          Storrs, CT

          Gabriella Scala, PharmD Candidate 2022
          UConn School of Pharmacy
          Storrs, CT 

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          • Sara Miller, Kyra Durfee and Gabriela Scala have no relationships with ineligible companies and therefore nothing to disclose.

          Disclaimer

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Content

          Post Test

          1. Which of the following is NOT a use for metrics in pharmacies?
          A. Quantify workflow
          B. Exhaust staff
          C. Establish comparators

          2. Patient-centered metrics are based on which of the following?
          A. Profits
          B. Public health initiatives
          C. Patient complaints

          3. _____ is a metric used to assess productivity.
          A. Time-to-fill
          B. Rate of medication errors
          C. Out-of-stock prescriptions

          4. Which of the following is a good way to reach vaccination metrics?
          A. Letting the patient contact the pharmacy about vaccinations
          B. Reminding patients of vaccinations at the register
          C. Relying on advertising to encourage patients

          5. What does SMART goals, a great way to develop an approach to improve metrics, stand for?
          A. Specific, Measurable, Achievable, Relevant, Time-Bound
          B. Specific, Measurable, Achievable, Resourceful, Time-Bound
          C. Specific, Measurable, Accurate, Reasonable, Time-Bound

          6. What is the most important skill in the workplace when tackling metrics?
          A. Speed
          B. Communication
          C. Knowledge

          7. Many metrics focus on efficiency. What other consideration is crucial?
          A. Type of pharmacy
          B. Patient safety
          C. Workload or volume

          8. Select the statement that is TRUE:
          A. Metrics usually refer to a general aspect of pharmacy tasks, so they are the same in community and clinical settings.
          B. While metrics often refer to a general aspect of pharmacy tasks, they can vary greatly between community and clinical settings.
          C. While metrics often refer to a general aspect of pharmacy tasks, pharmacies should stay away from standard metrics and develop new approaches.

          9. Super Tech is worried about her pharmacy’s time-to-fill metric. Wonder Pharmacist is focused on inventory metrics. Three months go by and they haven’t made good progress on either. Why?
          A. They are working alone on each metric, but need to be working together.
          B. It’s not possible to work on two metrics at the same time.
          C. Improving time-to-fill metrics will adversely influence inventory metrics.

          10. Which of the following activity falls heavily on pharmacy technicians and contributes heavily to pharmacy metrics in the community setting?
          A. Vaccinations
          B. Insurance and billing
          C. In-person patient interaction

          Handouts

          VIDEO

          NDMA Contamination Drives Recent Drug Recalls: What Do We Need to know?

          Learning Objectives

          At the end of this continuing education activity, the pharmacist will be able to:

          1. Describe details of recent ranitidine and metformin drug recalls
          2. Differentiate between categories of drug recalls
          3. Identify appropriate patient education regarding recalled medications

           

          At the end of this continuing education activity, the pharmacy technician will be able to:

          1. Describe details of recent ranitidine and metformin drug recalls
          2. Differentiate between categories of drug recalls
          3. Identify when referral to a pharmacist is appropriate

          Session Offered

          Release Date: February 22, 2024

          Expiration Date:  February 22, 2027

          Course Fee

          $4 Pharmacist

          $2 Technician

          Session Codes

          Pharmacist: 21YC05-XTR58

          Pharmacy Technician :  21YC05-RXT82

          ACPE UANs

          Pharmacist: 0009-0000-24-010-H05-P

          Pharmacy Technician :  0009-0000-24-010-H05-T

          Accreditation Hours

          1.0 hours of CE

          Accreditation Statements

           

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

          Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.1 CEU (1 contact hours) for completing the activity ACPE UAN 0009-0000-24-010-H05-P/T, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

           

           

          Grant Funding

          None

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

          Faculty

          Ariana Hawkins is a 2021 PharmD candidate

          Jeannette Y. Wick, R.Ph., MBA, FASCP, is the Assistant Director, Office of Pharmacy Professional Development, at the University of Connecticut.

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Ariana Hawkins and Jeannette Wick do not have any financial relationships with ineligible companies.

          Abstract

          The unexpected presence of N-nitrosodimethylamine (NDMA) in prescription and over-the-counter drug products precipitated several drug recalls in the last few years. Its presence has been troubling for the pharmaceutical industry and patients alike. With many questions unanswered, pharmacists and pharmacy technicians need to know the basics about this recall: the affected products, how NDMA may have contaminated various products, and appropriate actions and the timeframe in which to take them. This continuing education activity explains the recent recalls and provide current information.

           

           

          Content

          CONTENT

          A drug recall is a public notification of a product removed from the market due to a defective or harmful ingredient or label.1 Recalls are voluntary if initiated by the company or manufacturer. The United States (U.S.) Food and Drug Administration (FDA) initiates an involuntary recall when it finds a drug (or device) defective or harmful to consumers and the drug company does not issue a recall voluntarily.

          Recalls happen every year, as the FDA has measures in place to ensure consumer safety.1 The most common reasons for drug recalls are contamination, mislabeling, defective drug products, adverse reactions, newly published clinical studies, and incorrect drug potency.2 A classification system is in place to determine the level of harm the recalled product may cause (see the Technician Talk: Classifying Recalls2).1 The FDA also posts weekly enforcement reports containing pertinent information to inform the public about recalls.

          TECH TALK SIDEBAR: Classifying Recalls2

          The FDA classifies recalls into three categories that range in level of severity:

          1. Class I recalls are most severe, and product use might lead to serious health problems or death.
          2. Class II recalls are most common and can cause non-life-threatening adverse events or a slight threat of a serious event.
          3. Class III recalls are least severe and less likely to cause harm; often these are related to a labeling concern or a manufacturing citation.

          Sometimes, a recall is “unclassified,” meaning the FDA has not classified the recall yet but wants to inform stakeholders as soon as possible.

          This continuing education activity discusses the most recent recalls involving ranitidine/nizatidine and metformin.

          The FDA classifies recalls into three categories that range in level of severity:

          1. Class I recalls are most severe, and product use might lead to serious health problems or death.
          2. Class II recalls are most common and can cause non-life-threatening adverse events or a slight threat of a serious event.
          3. Class III recalls are least severe and less likely to cause harm; often these are related to a labeling concern or a manufacturing citation.

          Sometimes, a recall is “unclassified,” meaning the FDA has not classified the recall yet but wants to inform stakeholders as soon as possible.

          Not all recalls are announced on fda.gov, published in the media, or released to the public.1 The FDA notifies the public when a recall poses a serious health hazard or involves a widely distributed product.1 Otherwise, patients learn of recall information from drug manufacturers, their primary care physicians, or their local pharmacy.1 When the recall is widespread—meaning it affects many Americans—the media also announces it.

          Some of the most significant drug recalls from the past include3-5

          • Terfenadine (Seldane) in 1997: a non-sedating antihistamine formerly used to treat allergic rhinitis caused severe heart complications and potentially fatal drug interactions with certain antibiotics and antifungal medications
          • Astemizole (Hismanal) in 1999: a second-generation antihistamine used for treating allergy symptoms led to rare but potentially fatal cardiac side effects
          • Fenfluramine/phentermine (Fen-Phen) in 1997: a prescription weight loss medication that was associated with cases of pulmonary hypertension and many lawsuits
          • Rofecoxib (Bextra) in 2004: an anti-inflammatory drug used to treat arthritis linked to increased heart attack and stroke risk
          • Valdecoxib (Vioxx) in 2005: an anti-inflammatory drug linked to heart, stomach, and severe skin reactions, such as Stevens-Johnson Syndrome

          Drug recalls can leave patients feeling vulnerable and create or deepen mistrust between some patients and the healthcare profession if handled poorly.6 As patients hear news of a drug recall, healthcare professionals can help them understand what to do. Healthcare providers must rely on trusted resources that are updated often for guidance. Interested individuals can go to fda.gov/safety/recalls-market-withdrawals-safety-alerts to register for emails, safety alerts, and notifications pertaining to drug recalls.7 Safety alerts and drug recall information is available for three years on the FDA’s website before being archived. Patients and healthcare professionals can search the FDA’s archived content for older recalls on fda.gov/about-fda/about-website/fdagov-archive.8

          NDMA is an N-nitrosamine with cancer-causing potential that is ubiquitous in the environment; it is present in water, soil, and the air in small amounts.15 Humans are primarily exposed to NDMA orally.16 Most everyone is exposed to low levels of NDMA because dairy products, meats, and vegetables often contain it in trace amounts.17 The average daily NDMA intake from food sources is about 1 microgram.15

          NDMA can end up in water, food, and medication we consume daily. It can be generated from chemicals used to disinfect plants and therefore contaminate the public drinking water supply.16 Plants and animals subsequently use the water and the animals eat the plants. Additionally, when treatment plants chlorinate and disinfect waste- and drinking-water using chloramines, NDMA is an unintended byproduct.16  NDMA was historically used in the production of rocket fuel, antioxidants, softeners for copolymers, and lubricants which could contaminate the water and soil.16,18 Today, people only produce NDMA in its pure form for research purposes.

          NDMA’s cancer-causing potential stems from structural mutations that arise through its metabolic activation and covalent interaction with deoxyribonucleic acid (DNA).15 If these mutations persist throughout DNA’s replication cycle, permanent damage in critical sites may result.15

          NDMA may have contaminated medications in various ways. The first is cross-contamination from merging solvents and catalysts from factories in different industries. Solvents and catalysts that convert precursor chemicals into active ingredients become less effective over time. They should be segregated from other solvents to avoid cross contamination. ARBs are believed to have fallen victim to this phenomenon. Multiple manufacturers of finished pharmaceutical products acquired contaminated active ingredients because the solvents and/or catalysts used to produce them were tainted.16,17

          NDMA contamination of ranitidine and nizatidine is through one or both of the following16,18:

          • a direct byproduct of chemical reactions needed to produce the active ingredients
          • breakdown of the active ingredient itself

          The ranitidine molecule contains both a nitroso group and dimethylamine (DMA) group on either end of the molecule. NDMA is formed when the nitroso group and DMA group are near one another and a chemical reaction occurs.6

          It is currently unclear to what extent the aforementioned mechanisms drove the NDMA contamination of metformin ER products. Researchers examining drug products to detect their NDMA levels sometimes find either an nitroso group or a DMA group, but not both. They suggest the breakdown of unstable byproducts, side reactions during drug synthesis, and recycled solvents used in manufacturing could have led to NDMA formation and contamination of medications.6

          Different manufacturers’ drug processing methods and extreme medication storage temperature conditions may account for the varying NDMA levels found within drug products. Extreme temperature conditions can liberate the nitroso or the DMA and galvanize formation of NDMA in medications. It is unclear whether its formation stems from extreme temperature exposure by the manufacturer or from patients doing the same during their daily activities.18 Researchers detected increasing NDMA levels over an extended period and temperature conditions in some ranitidine products, posing a health concern for patients. 15,18

          Discovering a Discrepancy

          The interest in NDMA as a possible carcinogen arose from experimental animal studies.15 Several studies found that NDMA caused cancer, cirrhosis, and hyperplastic nodules in monkeys, classifying it as possibly carcinogenic to humans.15 Following these studies, additional research led to the discovery of this possible carcinogen in the drugs discussed here.

          A research associate at Valisure—an analytical pharmacy—discovered NDMA contamination in ranitidine prescribed to the company’s cofounder’s daughter.6 Using mass spectrometry and gas chromatography, the associate noted giant peaks on the test printout that indicated the presence of NDMA in ranitidine oral solution.6 The peaks’ intensity was so high that the research associate ran several tests to ensure the validity of the results. This discovery was not an isolated incident, as researchers from other companies have detected the presence of NDMA in medications taken by millions of people each year.6 It was, however, the instigator of the most recent recalls.

          Too much of any one ingredient or item can be toxic. The FDA indicates that a safe daily ingestion NDMA found in medications is 96 nanograms.15 The lowest amount of NDMA found by Valisure in ranitidine was 4 nanograms and the highest was 860 nanograms.6,15 Recalled metformin ER formulations also exceeded the allowable daily limit for products containing NDMA or N-nitrosamine-related compounds.19 A flaw in the FDA’s acceptable limit of NDMA per tablet or capsule is that some drugs are dosed multiple times per day, increasing daily exposure. Additionally, patients taking multiple drugs with NDMA concentrations just under the acceptable limit could have extensive aggregated exposure each day.

          Pause & Ponder: How do you counsel patients on protecting their medications from extreme temperatures over extended periods of time?

          Healthcare providers are vital in addressing patients’ questions and concerns about medication recalls. Ranitidine is no longer on the market, and prescribers are switching their patients to alternative medications.20,21 FDA testing of famotidine, cimetidine, lansoprazole, omeprazole, pantoprazole, and esomeprazole have not revealed NDMA contamination, so these are viable options to recommend.11 Patients taking metformin ER should continue to take their medication until they are able to speak to their provider or pharmacist.19 They should also contact their provider or go to the hospital if they experience severe or unusual side effects from their current therapy.

          Many patients will consult with a pharmacist—their accessible, local drug experts—for guidance. The pharmacy team should be ready to answer patients’ inventory-related questions pertaining to ranitidine and metformin ER. It is important to note that not all manufacturers of these medications are included in the recall. Patients often contact pharmacies to inquire if their medication has been recalled. Pharmacies with unrecalled metformin ER in stock should provide that specific manufacturer to patients to prevent lapses in therapy.

          Pharmacists can contact prescribers to discuss concerns and alternative treatment options. They can suggest alternatives to ranitidine, such as famotidine, cimetidine, or proton pump inhibitors (e.g., lansoprazole, omeprazole, pantoprazole, esomeprazole). Pharmacists can also assist in finding an appropriate dose of unrecalled metformin ER for patients before straying from their original therapy. Unrecalled metformin ER is preferred before requesting a medication change, as most patients are accustomed to the long-acting formulation and drastic changes in blood glucose levels can be hazardous. If an appropriate formulation is unavailable, pharmacists can assist physicians in converting metformin ER to immediate release dosing for patients with type 2 diabetes.

          PAUSE & PONDER:  Have you, a family member, or friend ever been affected by a drug recall? If so, how were you informed of the recall and what steps did you take next?

          Common Drugs with a Common Contaminant

          In November 2018, chemists had the first inkling that N-nitrosodimethylamine (NDMA) might be a medication contaminantChemists found NDMA impurities in the angiotensin receptor blocker (ARB) class of medications, otherwise known as the “sartans”.9 Several pharmaceutical companies recalled valsartan, losartan, and irbesartan because they contained NDMA and a related compound, N-nitrosodiethylamine (NDEA).10

          The FDA published a Class II recall for ranitidine due to potentially cancer-causing NDMA found in certain formulations in September 2019.11,12 Ranitidine is a histamine 2 receptor antagonist (H2RA) indicated for gastroesophageal reflux disease, heartburn, stomach ulcers, and other related conditions that cause stomach acid overproduction. Pharmacists and pharmacy technicians should advise patients that this recall affects prescription and over-the-counter (OTC) versions of ranitidine, one of which is the popular brand Zantac.14 The FDA has also found NDMA in another H2RA, nizatidine (Axid), which shares a similar chemical structure to ranitidine. It is also indicated to treat conditions caused by overproduction of stomach acid. As of April 2020, Amneal and Mylan voluntarily recalled nizatidine oral solution (15 mg/mL) and oral capsules, respectively, as each contained NDMA levels exceeding the acceptable daily intake limit of 96 nanograms.11

          The FDA also announced an unclassified metformin recall in June 2020.13 This recall does not apply to metformin immediate release formulations; it only pertains to certain extended release (ER) versions of the drug.13 Metformin ER is an antihyperglycemic medication indicated for patients with type 2 diabetes. Patients should confer with their pharmacist or other healthcare provider to determine an appropriate switch to a safer alternative. More guidance on appropriate counseling appears below.

          These recalls have affected millions of patients because those with common health conditions—acid reflux and diabetes—take ranitidine and metformin ER routinely and chronically. Many companies, including Apotex, Aurobindo, Dr. Reddy’s, Mylan, Lupin, Sandoz, Sanofi, Teva, and others, have recalled their drug products containing unacceptable NDMA levels.13 Data collection for both recalls is ongoing as the FDA continually posts updates on fda.gov/safety/recalls-market-withdrawals-safety-alerts.7

          Table 1 compares drug information of metformin ER and immediate-release metformin.19,22-24

          Table 1. Comparison of Metformin ER and IR19,22-24
            Metformin ER Metformin IR
          Doses 500 mg, 750 mg, 1000 mg 500 mg, 850 mg, 1000 mg
          ER to IR dosing Once daily ER = twice daily IR

          Twice daily ER = three times daily IR

          Twice daily IR = once daily ER

          Three times daily IR = twice daily ER

          Frequency Once or twice daily Twice or three times daily
          Patient Adherence Better than IR Worse than ER
          Pharmacokinetics Peaks slower, but lasts longer in the body (4 to 8 hours) Peaks faster, but has a shorter duration within the body (2 to 3 hours)
          Side Effects Fewer gastrointestinal side effects (e.g., diarrhea, nausea, vomiting) More gastrointestinal side effects (e.g., diarrhea, nausea, vomiting)

          ER=extended release; IR=immediate release

           

          Pause & Ponder: What strategies you have tried in the past to reassure patients amid a drug recall?

          Conclusion

          Medication recalls can be confusing and scary for patients, and pharmacy teams should be prepared to help them navigate next steps. Reassure patients that manufacturers are being more stringent in testing for NDMA. In light of the widespread recall, companies producing metformin-containing ER products are evaluating their medications cautiously for the presence of NDMA. If any tested batch is unacceptable, companies will not release it.13 Other companies producing NDMA-containing medications, including ranitidine, nizatidine, and antihypertensives, are also continually testing their products for NDMA to ensure the safety of products stocked within pharmacies.

          Discovery of NDMA impurities within several common medications for chronic conditions has highlighted its potential as a possible human carcinogen. Clinical literature to suggest NDMA’s clear correlation with cancer in humans is scant at this time. Future research and pharmacoepidemiologic studies are needed to establish a distinctive link between patients taking ranitidine and/or metformin and their exposure to NDMA.

          Post Test for Pharmacist

          Pharmacist Post-test Questions

          Question 1:  Mr. Taylor takes over-the-counter ranitidine for acid reflux. He heard news of a recent recall online pertaining to ranitidine products. He approaches the consultation counter to ask you for guidance. He has tried antacids without any relief. What do you advise Mr. Taylor to do?

          1. Continue taking the ranitidine he has at home because it was backordered, not recalled
          2. Contact his doctor because you are unsure of the right medication to recommend
          3. Take over-the-counter famotidine since it is safe and therapeutically equivalent

          Question 2:  The FDA has classified ranitidine as a class two recall. Which description below appropriately classifies a Class II recall?

          1. Can cause non-life-threatening adverse events or a slight threat of a serious event
          2. Most severe and use of the product might lead to serious health problems or death
          3. Least severe and less likely to cause harm; often related to a labeling concern

          Question 3: Mrs. Banks hears about a metformin recall through a friend and calls your pharmacy to ask if her metformin ER has been recalled. You check the lot numbers, realize that the manufacturer she received is on the recall list, and inform Mrs. Banks of this news. She is frantic and no longer wants to take her medication. What is the best advice for Mrs. Banks?

          1. “You’re right, Mrs. Banks. It is not safe to continue taking metformin ER because it has been recalled. You should schedule an appointment with your doctor as soon as possible to discuss other medications you can take instead.”
          2. “I understand why you want to stop taking your medication, but it is best to continue taking it to control your blood sugar until you are able to speak with your doctor. If you’d like, I can reach out to your doctor to discuss alternative medications to manage your diabetes. How does that option sound to you?”
          3. “I understand your concerns, Mrs. Banks, but it is not safe to completely stop taking your medication. You wean off the medication slowly from once daily to one tablet every other day until you are able to see your doctor about switching your therapy regimen.”

          Pharmacy Technician Post-test Questions

          Pharmacy Technician Post-test Questions

          Question 1: Mr. Taylor approaches the pharmacy counter looking for a medication to treat his acid reflux. He has been taking over-the-counter ranitidine for many years, but due to the recent recall, he feels it is unsafe continuing to take it. He has also tried antacids without relief. What do you recommend to Mr. Taylor?

          1. Tell Mr. Taylor to continue taking the ranitidine he has at home because it was not recalled and is only on backorder
          2. Instruct Mr. Taylor to contact his prescriber because you are unsure of the right medication to recommend
          3. Refer Mr. Taylor to the pharmacist who can recommend a therapeutically-equivalent medication to treat his acid reflux

          Question 2: The FDA has classified ranitidine as a Class II recall. Which description below appropriately classifies a Class II recall?

          1. Can cause non-life-threatening adverse events, or a slight threat of a serious event
          2. Most severe and use of the product might lead to serious health problems or death
          3. Least severe and less likely to cause harm; often related to a labeling concern

          Question 3: Mrs. Banks is picking up her prescription for metformin ER at the pharmacy, and she is concerned about a recent metformin recall she heard about from a friend. You check the lot numbers and confirm that the manufacturer Mrs. Banks takes was not recalled. She asks you if she should continue taking her metformin or to stop taking the medication. What is the best response to tell Mrs. Banks?

          1. “I am not sure if you should continue or stop taking your medication, but I can let the pharmacist know you would like to speak to him/her. Do you mind waiting a few moments for the pharmacist to answer your question?”
          2. “You’re right, Mrs. Banks. There has been a recall on metformin medications, but not all the manufacturers were affected. You should still continue to take your medication. Would you like to speak to the pharmacist about the different options available to you?”
          3. “You’re right, there has been a recall on all metformin medications. You should not pick up this medication and speak to your doctor right away about switching to an alternative medication."

          References

          Full List of References

          1. U.S. Food & Drug Administration. FDA’s role in drug recalls. Updated July 3, 2018. Accessed at https://www.fda.gov/drugs/drug-recalls/fdas-role-drug-recalls, July, 21, 2020.
          2. Hall K, Stewart T, Chang J, Freeman MK. Characteristics of FDA drug recalls: A 30-month analysis. Am J Health Syst Pharm. 2016;73(4):235-240.
          3. U.S. Food & Drug Administration. Safety: market withdrawals/recalls. Updated September 15, 2009. Accessed at https://wayback.archive-it.org/7993/20170405031504/https://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180605.htm, July 24, 2020.
          4. Gottlieb S. Antihistamine drug withdrawn by manufacturer. BMJ. 1999;319(7201):7.
          5. Handler Henning & Rosenberg, LLP. 5 Significant drug recalls in U.S. history & why they happened. October 7, 2019. Accessed at https://www.hhrlaw.com/blog/2019/october/5-significant-drug-recalls-in-us-history-why-the/, July 21, 2020.
          6. Boerner LK. NDMA, a contaminant found in multiple drugs, has industry seeking sources and solutions. Chemical & Engineering News. April 20, 2020. Accessed at https://cen.acs.org/pharmaceuticals/pharmaceutical-chemicals/NDMA-contaminant-found-multiple-drugs/98/i15, July 22, 2020.
          7. U.S. Food & Drug Administration. Recalls, market withdrawals, and safety alerts. Updated July 20, 2020. Accessed at https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts, July 21, 2020.
          8. U.S. Food & Drug Administration. FDA.gov archive. Updated April 21, 2019. Accessed at https://www.fda.gov/about-fda/about-website/fdagov-archive, July 21, 2020.
          9. Charoo NA, Ali AA, Buha SK, Rahman Z. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech. 2019;20(5):166.
          10. Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato - anatomy of the angiotensin-receptor blocker recalls. N Engl J Med. 2019;380(17):1589-1591.
          11. U.S. Food & Drug Administration. FDA updates and press announcements on NDMA in Zantac (ranitidine). April 16, 2020. Accessed at https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine, July 21, 2020.
          12. Blue Cross Blue Shield Blue Care Network of Michigan. Drug recall list. Updated June 2020. Accessed at https://www.bcbsm.com/content/dam/microsites/medicare/documents/drug-recall-list.pdf, July 21, 2020.
          13. American Academy of Family Physicians. FDA issues recall alert for metformin ER products. June 1, 2020. Accessed at https://www.aafp.org/news/health-of-the-public/20200601metforminrecall.html, July 22, 2020.
          14. U.S. Food & Drug Administration. Question and answers: NDMA impurities in ranitidine (commonly known as Zantac). Updated April 01, 2020. Accessed at https://www.fda.gov/drugs/drug-safety-and-availability/questions-and-answers-ndma-impurities-ranitidine-commonly-known-zantac, July 21, 2020.
          15. Adamson RH, Chabner BA. The finding of N-nitrosodimethylamine in common medicines. Oncologist. 2020;25(6):460-462.
          16. United States Environmental Protection Agency. Technical fact sheet–N-nitroso-dimethylamine (NDMA). January 2014. Accessed at https://www.epa.gov/sites/production/files/2014-03/documents/ffrrofactsheet_contaminant_ndma_january2014_final.pdf, July 21, 2020.
          17. U.S. Food & Drug Administration. Information about nitrosamine impurities in medications. Accessed at https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications, July 21, 2020.
          18. White CM. Understanding and preventing (N-Nitrosodimethylamine) NDMA contamination of medications. Ann Pharmacother. 2020;54(6):611-614.
          19. U.S. Food & Drug Administration. FDA updates and press announcements on NDMA in metformin. Accessed at https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin, July 21, 2020.
          20. American Society of Health-System Pharmacists. Current drug shortages: ranitidine injection. April 2, 2020. Accessed at https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=426, July 21, 2020.
          21. U.S. Food & Drug Administration. FDA requests removal of all ranitidine products (Zantac) from the market. April 1, 2020. Accessed at https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market, July 21, 2020.
          22. Metformin [prescribing information]. Raleigh, NC: Indicus Pharma LLC;2020. Accessed at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56d13a1c-b289-4528-b23c-60f5427b4552, July 21, 2020.
          23. Pala L, Rotella CM. The "slower" the better. J Endocrinol Invest. 2014;37(5):497-498.
          24. Metformin ER [prescribing information]. Parsippany, NJ: Granules USA, Inc;2019. Accessed at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b857eccf-b9ff-45ba-8241-f47f5caada2a, July 21,2020.
          25. White CM. Dietary supplements pose real dangers to patients. Ann Pharmacother. 2020;54(8):815-819.